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ABSTRACT
Evaluation of the Mechanisms of Anti-Cancer Immune Responses
Noel Turner
2019
Metastatic melanoma historically carries a grim prognosis, with a median survival
of 9 months and a long-term survival rate of 10%. Melanoma is highly immunogenic, and
the development of immunotherapies has dramatically changed the landscape of
metastatic melanoma treatment. To study the immune mechanisms engaged by these
therapies, the Bosenberg lab developed YUMMER, an immunogenic mouse melanoma
line that forms tumors when injected into mice. This and other immunogenic murine
cancer models were used to demonstrate that B cell depletion does not impair the antiPD-1-induced anti-tumor immune response in mice. In addition, supplementing immune
checkpoint inhibition with therapies targeting myeloid cells increases the efficacy of
immune checkpoint inhibitors and can convert resistant tumors into sensitive tumors.
Last, a novel model was developed that allows for comparison of failed and successful
anti-tumor immune responses, and we propose how it may be employed to study the
role of T cell dysfunction in immune checkpoint inhibitor resistance.
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Chapter One: Background and Literature Review

Melanoma is a malignant neoplasm of melanocytes that accounts for the majority
of skin cancer deaths despite comprising less than 5% of all cutaneous malignancies (1,
2). Its incidence has increased faster than that of any other cancer over the past halfcentury, and the annual costs of treatment in the United States alone have risen rapidly
(1, 3-6). Although the majority of primary melanomas are cured with local excision,
metastatic melanoma historically carries a grim prognosis, with a median survival of 9
months and a long-term survival rate of 10% (7, 8). Given the urgent need to develop
treatment strategies for metastatic melanoma, there has been extensive research into
both the genetic alterations that cause melanocytes to become malignant as well as the
interactions between melanoma cells and the immune system. The knowledge gained
from this research has led to the development of animal models of melanoma, which
have, in turn, informed novel treatment strategies. This chapter will first review the
genetic changes thought to contribute to the malignant features of melanoma. It will then
examine the current therapeutic landscape for metastatic melanoma with a particular
emphasis on immunotherapy. Finally, it will explain the development and characteristics
of the Yale University Mouse Melanoma (YUMM) model and its irradiated counterpart,
the Yale University Mouse Melanoma Exposed to Radiation (YUMMER) model.

A. The Genetics of Melanoma
1) Cutaneous Melanoma
Cutaneous melanomas have historically been classified into superficial
spreading, nodular, lentigo maligna, desmoplastic, mucosal, or acral subtypes based
upon anatomic site and histologic morphology (9). The most common subtype is
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superficial spreading melanoma, which is thought to originate in the epidermis before
entering a vertical growth phase and invading into the dermis. In contrast, nodular
melanoma is thought to progress to a vertical growth phase more rapidly. Lentigo
maligna melanoma presents as a slow-growing macule or patch in sun-exposed skin
and typically affects elderly patients. Desmoplastic melanoma is also associated with
sun exposure, is locally infiltrative, and has a lower rate of metastasis to draining lymph
nodes. Mucosal melanoma affects mucous membranes while acral melanoma affects
palmoplantar and subungual skin. Mucosal and acral melanomas share the
characteristic that they typically have less sun exposure than other forms of cutaneous
melanoma and are frequently classified together as acral lentiginous melanomas (ALM)
(10, 11). ALM accounts for less than 3% of all primary melanomas (12, 13) but is the
most common subtype in people of African and Asian heritage and has a similar
incidence in all ethnicities and skin types (14).
The clinical utility of this classification scheme has been called into question,
however, both because a significant proportion of melanomas fail to fit neatly into a class
and because histologic subtype is not an independent prognostic factor (15). Recent
efforts examining the genetics of melanoma on a large scale have allowed for synthesis
of genetic data with the historic classifications, allowing for a greater understanding of
the biologic underpinnings of melanoma types and the role of sun exposure. In this
section, we will first review the role of ultraviolet radiation in melanomagenesis, then the
known genetic drivers that underlie cutaneous melanomas arising on intermittently sunexposed (non-CSD) skin, and follow with a discussion of melanomas associated with
either minimal (acral/mucosal) or chronic sun damage (CSD) (16).
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Ultraviolet signature
Exposure to ultraviolet radiation has long been considered an important
environmental risk factor for cutaneous melanoma. Genetic studies have supported this
notion, revealing that cutaneous melanomas harbor a very high somatic mutation burden
relative to other tumor types (17). Approximately 45% of mutations in melanoma are
cytosine-to-thymine or tandem CC-to-TT transitions, while approximately 10% are
guanine-to-thymine transversions (18). This is consistent with exposure to UV-B
radiation, which is known to cause crosslinking of adjacent pyrimidine bases (CC, CT,
TC, or TT). When recognized by DNA polymerases, two adenine bases are often
inserted opposite to the dimerized pyrimidines, and during the subsequent replication
cycle, the alteration is incorrectly repaired resulting in C-to-T or CC-to-TT transitions
(19). Less commonly, G-to-T transversions have been reported (20). Both the rates of
single nucleotide variants and mutations among melanomas are highest on CSD skin
and lowest in acral and mucosal sites (21).

Non-CSD melanoma
MAP Kinase pathway
Greater than 80% of melanomas on non-CSD skin have been found to harbor
mutations that constitutively activate the MAP Kinase/ERK signaling pathway, which
regulates cell proliferation and survival (11). Data from The Cancer Genome Atlas
(TCGA) cohort revealed that non-CSD melanomas can be classified into BRAF, RAS,
NF1, and triple-wild type subtypes based upon the most prevalent mutations affecting
this pathway (21). BRAF is the most commonly mutated gene and is altered in
approximately 50% of non-CSD melanomas. BRAF encodes a serine-threonine kinase
that phosphorylates MEK (MAP2K) when bound to active RAS-GTP (22, 23). Up to 90%
of BRAF mutations affect exon 15 and result in V600E substitutions that cause
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constitutive activation of BRAF (22); less common substitutions include V600K, V600R,
and K601E (21). Approximately 25% of melanomas contain mutations in NRAS, which
encodes a small G protein that binds to and activates BRAF when in the GTP-bound
state (21). Most NRAS mutations are found either within exon 1 leading to substitution of
glycine at position 12 or 13 or within exon 2 leading to substitution of glutamine at
position 61; in both cases, mutation prevents hydrolysis of GTP leading to constitutive
activation of both NRAS and its downstream effectors (11). In addition to NRAS, rare
mutations in HRAS (G13D, G13S, and Q61K) and KRAS (G12D, G12R, and Q61R)
were identified in tumors from the TCGA cohort (21). Of note, BRAF and RAS mutations
are seldom, if ever, detected in the same tumors (22). Other perturbations in the MAP
Kinase pathway include loss-of-function mutations in the genes for RAS GTPaseactivating proteins (GAPs) NF1 and RASA2 that are found in approximately 15% and 5%
of non-CSD melanomas, respectively (18, 24), and gain of function mutations in MEK1
(MAP2K1) and MEK2 (MAP2K2) that have been identified in 8% of non-CSD
melanomas (25). Interestingly, NF1 mutations were found to be anti-correlated with
BRAF mutations but not with NRAS mutations in tumors from the TCGA cohort (21).
Despite the prevalence of BRAF and NRAS mutations in non-CSD melanomas,
these mutations are insufficient to drive malignancy in isolation. It is well known that
benign acquired nevi and benign congenital nevi predominantly contain BRAF and
NRAS mutations, respectively (26, 27). BRAF mutations have also been shown to
induce growth arrest in vitro (28). This suggests that constitutive activation of BRAF
triggers checkpoint mechanisms designed to restrict malignant growth, a phenomenon
known as oncogene-induced senescence (OIS) (28). To overcome OIS, additional
mutations or epigenetic changes, often affecting the PI3 Kinase pathway and/or
CDKN2A, are necessary (29).
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PI3 Kinase pathway
Up to 50% of non-CSD melanomas exhibit mutations affecting the PI3 Kinase
pathway and its effectors (11). Inactivation of PTEN, a phosphatase that
dephosphorylates PIP3 and thereby inhibits the anti-apoptotic function of Akt, was
identified in 10% of tumors in the TCGA cohort, while other studies have reported PTEN
mutations, deletions, or epigenetic silencing in up to 30% of non-CSD melanomas (11,
30, 31). In addition to PTEN inactivation, gain-of-function mutations or amplifications
affecting the catalytic subunits of either PI3 Kinase (4%) or Akt (up to 30%) may be
present (32, 33). 4-9% of tumors contain mutations in the gene encoding RAC1, a small
G protein in the Rho family that induces lamellipodia formation and contributes to cell
motility downstream of PI3 Kinase and other pathways in vitro (11). The most commonly
identified mutation, a P29S substitution, is caused by a cytosine-to-thymine transition
consistent with UV-B exposure. This mutation results in increased GDP/GTP nucleotide
exchange that favors the active form of RAC1 and is thought to enhance cell migration
and proliferation (24, 34). Gain-of-function mutations in the gene encoding PREX2, a
guanine nucleotide exchange factor (GEF) for RAC1, were also found in 26% of nonCSD melanomas in the TCGA cohort, although its role as a driver mutation remains
unclear (35). Finally, greater than 15% of tumors in the TCGA cohort contain mutations
in components of the mTOR signaling pathway that operates downstream of Akt
including MTOR, TSC1, TSC2, RICTOR, and RPTOR (21).

CDKN2A
Although known for being the most commonly altered gene in familial melanoma,
somatic loss-of-function mutations in CDKN2A were found in 15% of tumors in the
TCGA cohort, and losses or epigenetic downregulation have been reported in up to 70%
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of sporadic melanomas (16, 36). This gene encodes both p16/INK4a, a G1-CDK
inhibitor, and p14/ARF, a protein that blocks MDM2-mediated degradation of p53 (11).

TERT
Mutations in the promoter region of telomerase reverse transcriptase (TERT), a
component of the telomerase holoenzyme, are found in up to 70% of melanomas (3740). Consistent with UV signature, cytosine-to-thymine transitions at one of four
positions upstream of the transcriptional start site have been shown to produce new
binding motifs for the ETS transcription factor GA-binding protein (GABP) that lead to
increased expression of TERT and therefore increased telomerase activity, which may
enable cells to overcome senescence (41).

MITF
The MITF locus on chromosome 3p is amplified in 10% of non-CSD melanomas
(36, 42). MITF, or microphthalmia-associated transcription factor, is a basic helix-loophelix transcription factor that is responsible for melanocyte differentiation and function
(42). It is known to control expression of several cell cycle regulators and proproliferative proteins including CDK2, TBX2, CDKN2A, p21, Bcl2, and c-Met as well as
HIF-1α, which is believed to promote tumor survival and metastasis (43). Additionally,
transcription of MITF is known to be upregulated by canonical WNT signaling through βcatenin, and gain-of-function mutations in CTNNB1 (β-catenin) are found in 5-7% of nonCSD melanomas (44).

Other genes
Analysis of the TCGA cohort has led to the implication of several other genes in
melanoma tumorigenesis. 34% of tumors contain somatic mutations in GRIN2A, the
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gene encoding the ionotropic glutamate receptor NMDAR2A, that prevent NMDA-R
complex formation, increase anchorage-independent growth, and increase cell migration
in vitro (45). Similarly, 23% of tumors contain somatic mutations in GRM3, the gene
encoding metabotropic glutamate receptor 3, that have been shown to disrupt
melanosome trafficking via dysregulation of cAMP signaling (46, 47). Approximately 16%
of non-CSD melanomas were found to harbor loss-of-function mutations in TP53, which
encodes a protein that restricts cell cycle progression in response to DNA damage (18,
21, 37). In addition, upregulation of MDM2 and MDM4, E3 ubiquitin ligases that signal
p53 degradation, has also been observed in a subset of tumors (48). 7% of tumors
contain mutations in PPP6C, the gene encoding a phosphatase known to restrict G1-toS phase transition (18, 49). 7% contain mutations in ARID2, a gene encoding a
component of the PBAF chromatin-remodeling complex and known tumor suppressor
(18). 6% of tumors contain mutations in DDX3X, a gene encoding a DEAD-box RNA
helicase involved in translation initiation and stress granule assembly, resulting in
globally reduced translation that may provide a survival advantage to tumor cells (50).
Less common mutations affect citric acid cycle enzyme IDH1 (5.7%), tumor suppressor
RB1 (4.3%), 40 S ribosomal protein RPS27 (2.6%), and mitochondrial ribosomal protein
MRPS31 (1.3%) (21, 51).

Chromosomal aberrations
Prior to the advent of deep sequencing technology, cytogenetic approaches were
used to study the genetics of melanoma. Commonly reported alterations found in nonCSD cutaneous melanomas include losses on chromosomes 1p, 4, 5, 6q, 8p, 9p, 10q,
11q, 12q, 14, 15, 16, 21, and 22 and gains on chromosomes 1q, 6p, 7, 8q, 18, and 20q;
of note, AKT3 is located on chromosome 1q, BRAF is located on chromosome 7q, and
CDKN2A is located on chromosome 9p (11, 52-54).
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Acral, mucosal, and CSD melanoma
Chromosomal aberrations
Several studies have shown that acral and mucosal melanomas harbor
significantly increased chromosomal aberration when compared to both non-CSD and
CSD melanomas (16, 55, 56). Up to 89% of acral melanomas and 85% of mucosal
melanomas have been shown to contain gene amplifications, in contrast to infrequent
amplifications found in both non-CSD and CSD melanomas (13, 16). The most
commonly identified structural variations include gains in 4q, 5p, 6p, 11q, 12q, and 22q
and losses in 6q, 9p, and 10 (16, 54, 56, 57), many of which upregulate the activity of
the G1-S cyclin-dependent kinase. In particular, 10% of acral or mucosal melanomas
have gain in the CDK4 gene on chromosome 12q, up to 45% demonstrate gain in the
CCND1 gene on chromosome 11q, and approximately 60% demonstrate loss in the
CDKN2A gene on chromosome 9p (13, 55, 58).

KIT and PDGFRA
Unlike non-CSD melanomas, amplifications of chromosome 4q containing the
gene for the receptor tyrosine kinase KIT are found in approximately 30% of mucosal
melanomas and 25% of acral melanomas while gain-of-function mutations are found in
approximately 20% of mucosal melanomas and 10% of acral melanomas (13, 59). 28%
of CSD melanomas also harbor KIT mutations or amplifications (59). Among ALM and
CSD melanomas, KIT alterations are rarely if ever found in tumors that also contain
BRAF or NRAS mutations (59). Most KIT mutations occur in exon 11, 13, 17, or 18, and
the most common mutations are the substitutions L576P on exon 11, K642E on exon 13,
and V559A on exon 11 (37, 38, 60), resulting in constitutive kinase activity and
stimulation of both the MAP Kinase and PI3 Kinase pathways (61). Of note, this
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spectrum of mutations overlaps with that of both sporadic and familial gastrointestinal
stromal tumors (44, 62).
Also located on chromosome 4q, the gene for receptor tyrosine kinase PDGFRA
is commonly amplified in ALM (21, 55). Gain-of-function mutations in the gene have also
been reported in up to 6.8% of acral melanomas and 3.6% of mucosal melanomas (13,
63). These mutations cause ligand-independent activation of the receptor leading to
dysregulated melanocyte proliferation, differentiation, and migration (63, 64). Notably,
PDGF is thought to play a role in melanocyte epithelial-to-mesenchymal transition (EMT)
that precedes metastasis (65). In contrast to ALM, neither CSD nor non-CSD
melanomas commonly contain aberrations in PDGFRA (63).

BRAF and NRAS
Unlike non-CSD melanomas, ALM and CSD melanomas less commonly contain
mutations in BRAF. Although reports vary, BRAF mutations are found in approximately
3-11% of mucosal melanomas, 21-23% of acral melanomas, and 6-11% of CSD
melanomas (16, 44, 55). In contrast to BRAF mutations, NRAS mutations occur at a
similar rate of approximately 10-25% among acral, mucosal, CSD melanomas, and nonCSD melanomas (66).

Other genes
Other genes that have been implicated in acral or mucosal melanoma include
MITF, PREX2, ARID1A, PTEN, TP53, AURKA, and APC (18, 24, 35, 57, 67, 68). In
contrast to non-CSD melanomas, only 6-11% of ALM contain TERT promoter mutations
(55, 69). Up to 25% of acral melanomas, however, have been found to contain copy
number gains in the TERT gene (68). Mutations in DDX3X, RASA2, PPP6C, RAC1, or
RB1 are rarely reported in ALM (55).
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2) Ocular melanoma
Ocular melanoma is the most common primary malignancy of the eye among
adults (70), although it comprises only 5% of all melanoma (71). It arises in the uvea in
95% of cases and in the conjunctiva in the remaining 5% (70). Information regarding the
genetic alterations in conjunctival melanoma is scarce, but the available data suggest
that these tumors have more in common with cutaneous melanomas than uveal
melanomas. Indeed, BRAF, NRAS, and TERT mutations are commonly found in both
cutaneous and conjunctival melanomas but not in uveal melanomas (11, 72). Of note,
unlike cutaneous melanoma, uveal melanoma is not considered to be related to UV
exposure (73). Below, we will review the known genetic drivers of uveal melanoma.

GNAQ/GNA11
The most commonly mutated genes in uveal melanomas include GNAQ and its
paralog, GNA11, affecting 45% and 32% of primary uveal melanomas, respectively (74,
75). Both genes encode the α subunit of a heterotrimeric Gq protein that functions to
activate the protein kinase C, MAP Kinase, and YAP1 pathways via a phospholipase Cdependent mechanism (76). 97% of the reported mutations consist of Q209L or Q209P
substitutions in exon 5 while the remaining 3% consist of R183C substitution in exon 4;
all of these mutations impair the intrinsic GTP-ase activity, producing an increase in
downstream signaling (74, 75). Recently, activating mutations have been identified both
upstream and downstream of GNAQ/GNA11 signaling. In a subset of uveal melanomas,
a L129Q substitution in the gene encoding CYSLTR2, a leukotriene-sensing G-proteincoupled receptor (GPCR) that acts as a GEF for GNAQ/GNA11, has been shown to
favor the active conformation and increase GNAQ/GNA11 activity (77, 78). PLCB3 and
PLCB4, both genes that encode phospholipase C enzymes activated by GNAQ/GNA11,
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have recently been found to harbor K898N and D630Y substitutions, respectively,
although the role of these genes in oncogenesis is unclear (77, 79).

BAP1 and other genes
Up to 40% of uveal melanomas contain inactivating (usually truncating)
mutations affecting BAP1 (BRCA1 associated protein-1) (80, 81), a protein that has
been shown to play a role in DNA repair (82), melanocyte differentiation (83), and
epigenetic regulation of the RB1 gene (11, 71, 84). Recurrent mutations have also been
identified in EIF1AX, a gene encoding a component of the 43S preinitiation complex that
aids in recruitment of the 40S ribosomal subunit to mRNA, and SF3B1, a gene encoding
a component of the U2 small ribonucleoprotein (snRNP) involved in RNA splicing (81,
85). Of note, mutations in EIF1AX and SF3B1 occur almost mutually exclusive to each
other and to mutations in BAP1 (85).
Uveal melanomas are commonly classified into one of two prognostic groups
based on their gene expression profiles (86). Melanomas in the first group, which harbor
mutations in either EIF1AX or SF3B1, are associated with low risk of metastasis (85)
while melanomas in the second group, which harbor mutations in BAP1, are associated
with high metastatic risk (87). Approximately 80% of metastatic uveal melanomas
contain truncating mutations in BAP1 (80) and target the liver in up to 90% of cases (88).
Interestingly, BAP1 mutations usually arise early in tumor evolution and are followed by
a period of neutral evolution before tumors become clinically evident, suggesting that the
metastatic potential of uveal melanoma is determined early in its course (87).

Chromosomal aberrations
Commonly reported chromosomal aberrations in uveal melanoma include
monosomy of chromosome 3, gain in 1q, 6p, and 8q, and loss in 1p, 6q, 8p, and 16q
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(11, 54, 70, 71). Monosomy 3, found in up to 50% of cases, is associated with worse
prognosis and losses in BAP1 (located on chromosome 3p), while 8q gain is also
associated with worse prognosis (89).

3) Familial melanoma
Between 5 and 10% of cutaneous melanomas are thought to arise in the context
of a family history of melanoma (11, 90). Approximately 40% of these tumors are
associated with loss-of-function mutations in CDKN2A, resulting in loss of p16/INK4A, a
key negative regulator of cell cycle progression (90, 91). Additionally, germline gain-offunction mutations in CDK4 including R24C and R24H have been reported; these
mutations prevent the interaction between CDK4 and p16/INK4 resulting in increased
CDK4 activity and cellular proliferation (11, 92). Patients with familial retinoblastoma due
to germline alteration of the RB1 cell cycle regulator are also at increased risk for
cutaneous melanoma (93). Other candidate genes that may explain up to 2% of familial
cutaneous melanoma include BAP1 (94, 95) along with the genes encoding telomereassociated proteins POT1, ACD, TERF2IP, and TERT (96).
In addition to these highly penetrant yet rare mutations, more common single
nucleotide polymorphisms (SNPs) in MITF and MC1R have been associated with
intermediate risk of cutaneous melanoma (11). A recently discovered germline mutation
in MITF causing a E318K substitution has been found to impair post-translational
SUMOylation of MITF leading to increased transcription of its target genes including
CDK2, Bcl2, c-Met, and HIF-1α (43, 97-99). MC1R encodes the melanocyte stimulating
hormone receptor that controls MITF expression and the pigmentation process. Variants
in this gene have been associated with synthesis of the less photoprotective pigment,
pheomelanin, and the resulting red hair color phenotype (100). These variants also
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inhibit the interaction between MC1R and PTEN, allowing for increased activation of the
PI3 Kinase pathway (101).
1-2% of uveal melanomas are thought to be hereditary (11), although less is
known about the genetics of familial uveal melanoma than familial cutaneous melanoma.
Germline BAP1 mutations in uveal melanomas have been reported, and recent studies
have suggested that inherited BAP1 mutations predispose patients to cutaneous
melanoma, uveal melanoma, mesothelioma, renal cell carcinoma, and several other
tumors (71). In contrast to familial cutaneous melanoma, CDKN2A mutations and MC1R
variants do not seem to be associated with uveal melanoma (102).

Conclusion
Analysis of genomic data from large melanoma tumor cohorts has led to the
discovery of several genetic changes thought to drive melanomagenesis. In this section,
we reviewed these changes as well as the signaling pathways that they affect.
Importantly, this understanding of melanoma genetics has informed the development of
several targeted therapies now used to treat patients with metastatic disease. The
following section will discuss these and other therapeutic options in the treatment of
metastatic melanoma.
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B. Therapeutic Options for Metastatic Melanoma
As mentioned in the introduction, the majority of primary cutaneous melanomas
can be cured surgically, with margins of excision determined by the tumors’ depths of
invasion observed on biopsy: 5 mm margins are recommended for in situ melanomas, 1
cm margins are recommended for melanomas that are up to 1 mm in thickness, 1-2 cm
margins are recommended for melanomas that are 1-2 mm thick, and 2 cm margins are
recommended for melanomas that are thicker than 2 mm (103). In cases of metastatic
melanoma, however, surgery is rarely sufficient to achieve cure. Instead, other treatment
modalities including chemotherapy, targeted therapy, and immunotherapy are often used
in addition to or in lieu of surgical excision. In this section, we will review the current
therapeutic options for metastatic melanoma, placing particular emphasis on
immunotherapies, as these medications have shown the most promise in treating this
devastating disease.

1) Chemotherapy
Prior to the development of therapies targeting aberrant signaling cascades and
immune cells, treatment of metastatic melanoma often involved chemotherapy using the
alkylating agent dacarbazine or its prodrug, temozolomide (TMZ). While at one point the
standard of care for metastatic melanoma, dacarbazine therapy results in a complete
response in less than 5% of patients, a median progression-free survival of 2.2 months,
and a 5-year survival in only 2-6% of patients (104); TMZ has been shown to be even
less effective than dacarbazine (105). In both cases, the lack of efficacy is thought to be
due to melanoma cells’ inherent resistance to apoptosis (106). Although no longer the
standard of care for metastatic disease, dacarbazine and TMZ continue to be employed
in the treatment of refractory and relapsed melanomas (107).
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2) Targeted Therapy
The advancements in melanoma genetics reviewed in chapter 1A identified
several potential therapeutic targets that have since led to the development of novel
mutation-specific therapies. For this reason, genetic sequencing of melanoma tissue is
now an important component of a melanoma patient’s initial evaluation. Small molecule
inhibitors of BRAF including vemurafenib and dabrafenib, for example, have been
approved to treat metastatic melanomas that harbor gain-of-function mutations in BRAF
(108, 109). In clinical trials, vemurafenib was shown to improve clinical response rates,
progression-free-survival, and overall survival in patients with BRAF-mutant melanomas,
and up to 90% of tumors treated with vemurafenib demonstrated partial regression
(109). As previously discussed, mutations in NRAS and BRAF do not co-occur, and
therefore, BRAF inhibition is not a valid strategy for treating NRAS-mutant melanomas
(22).
Despite these promising findings, however, initially sensitive tumors quickly
develop resistance to BRAF inhibitors through multiple mechanisms including the
acquisition of activating mutations in genes encoding other MAP Kinase pathway
molecules such as MEK and NRAS as well as activation of the PI3 Kinase pathway via
loss of PTEN activity (110). In order to address this, inhibitors of MEK have been
developed, including trametinib and cobimetinib (111). When compared to
chemotherapy, trametinib monotherapy was reported to improve clinical response rates,
progression-free-survival, and overall survival in patients with BRAF-mutant melanomas
who had not received BRAF inhibitor therapy (112). Even better outcomes have been
seen with BRAF inhibitor/MEK inhibitor combination therapies including
trametinib/dabrafenib and cobimetinib/vemurafenib, which have been approved for
metastatic, BRAF-mutant melanomas (113). In patients with untreated and unresectable
BRAF-mutant metastatic melanoma, cobimetinib/vemurafenib has been shown to
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produce a complete or partial response in 69.9% of patients and a median progressionfree survival of 12.3 months, in contrast to the 50% response rate and 7.2-month median
progression-free survival in similar patients treated with vemurafenib alone (114). Since
the development of even more effective immunotherapies, however, these combination
regimens have been used in patients who either fail or cannot tolerate immune therapy.
In contrast to non-CSD melanomas, acral lentiginous and CSD melanomas often
harbor mutations or amplifications in KIT. For patients with these aberrations who have
failed or cannot tolerate immune therapy, small molecule tyrosine kinase inhibitors with
activity against KIT, including imatinib, sunitinib, dasatinib, and nilotinib, can be
employed (115). Clinical trials of imatinib therapy in patients with KIT-mutant melanomas
have shown an approximately 30% response rate with a median progression-free
survival of 3-4 months; patients with KIT amplifications are less responsive to targeted
therapy than are patients with KIT mutations (116-118).
In addition to medications directed against components of the MAP Kinase
pathway and KIT, several other targeted therapies are being evaluated for use in
metastatic melanoma. These include antibodies against vascular endothelial growth
factor (VEGF) such as bevacizumab, inhibitors of PI3 Kinase such as PI-103, mTOR
inhibitors such as rapamycin and everolimus, and CDK4/6 inhibitors including ribociclib;
many of the ongoing clinical trials are assessing whether combining these therapies with
other targeted therapies or immune therapies improves response rates and outcomes
(119-122).

3) Immunotherapy
Melanoma is known to be one of the most immunogenic tumor types, with
immune-mediated spontaneous regression occurring in approximately 3% of melanomas
(123). Further evidence of its propensity to spontaneously regress lies in the fact that 5%
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of melanoma patients present with metastases that harbor mutations classically found in
non-CSD melanomas but lack any sign of a primary tumor (124). The effector cell of this
anti-tumor immune response is thought to be the tumor-infiltrating lymphocyte (TIL), a
hypothesis supported by the observation that the density of TILs on histologic
examination of biopsied melanomas positively correlates with patient survival (125, 126).
TILs have been found to recognize melanocyte differentiation antigens including gp100,
tyrosinase, and MART-1/Melan-A (127-129); they have also been shown to recognize
the gene-products of aberrantly-expressed melanoma-associated genes (MAGE) as well
as neoepitopes formed from the expression of somatically-mutated genes (130). In light
of its strong association with UV exposure, it is perhaps unsurprising that cutaneous
melanoma has the greatest somatic mutation burden of any known cancer (18, 24).
Given the immune system’s ability to recognize and kill melanoma cells, it follows that
the development of immunotherapies has dramatically changed the landscape of
metastatic melanoma treatment.

Interferon α-2b
The first immune therapy was interferon (IFN) α-2b, a type I interferon that
activates natural killer (NK) cells, T cells, and dendritic cells in addition to suppressing
viral replication (131). IFN α-2b has been shown to both inhibit VEGF secretion by
melanoma cells and upregulate major histocompatibility complex (MHC) class I
expression on the surface of melanoma cells, allowing for increased recognition by
cytotoxic T cells and thus, increased apoptosis (132). IFN α-2b has been approved as
adjuvant therapy for patients with either high risk of disease progression following
excision or lymph node metastasis, and it has been shown to both reduce recurrence
risk and improve overall survival in patients whose tumors are responsive (133, 134).
The strongest predictors that a patient would benefit from adjuvant IFN α-2b therapy
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include ulceration of the primary tumor (135), high tumoral pSTAT1/pSTAT3 ratio (136),
high serum levels of pro-inflammatory cytokines including IL1β, IL-6, and TNF-α (137),
and dense infiltration of metastatic lesions by CD4+ lymphocytes (138).
A pegylated variant of IFN α-2b has also been approved for melanomas that
have metastasized to the lymph nodes (139). Peginterferon α-2b is formed through the
covalent attachment of a polyethylene glycol (PEG) moiety to IFN α-2b, resulting in a
compound with an increased half-life (140). Although shown to increase relapse-free
survival following tumor resection, it does not increase overall survival when compared
to observation alone (141). It is also associated with higher rates of immune related
adverse events (irAEs) than its non-pegylated counterpart (142).
In addition to monotherapy, combination therapies with IFN α-2b have been
evaluated for efficacy against metastatic melanoma. IFN α-2b has been combined with
IL-2, dacarbazine, cisplatin, and vinblastine to create “biochemotherapy,” which shows
higher response rates and increased progression-free survival when compared to
dacarbazine monotherapy; this regimen, however, is associated with significant toxicity
and does not increase overall survival (143). Studies evaluating the effects of combining
IFN α-2b with immune checkpoint inhibitors as well as BRAF inhibitors are currently
underway (131, 144).

Interleukin-2
Interleukin-2 (IL-2), a cytokine that stimulates the proliferation of T lymphocytes
(145), was approved for the treatment of metastatic melanoma after early trials
demonstrated objective partial responses in a subset of patients (146). A recent metaanalysis of over 3000 patients with metastatic melanoma demonstrated that high-dose
IL-2 therapy results in complete responses in 4% of patients and partial responses in
12.5% of patients, with an overall response rate of 19.7% (147). Despite the promising

19
anti-tumor effects of IL-2, however, it also causes increased capillary permeability and
fluid extravasation that manifest as a host of severe clinical toxicities including diarrhea,
shock, and even death (148). These severe toxicities have become less common in
recent years, as dosing regimens have been adjusted to reflect increased understanding
of the side effect profile; while the rate of treatment-related deaths was initially between
2% and 4%, it is now less than 1% (148). Although newer immune therapies have been
able to achieve similar response rates with less severe toxicities, IL-2 remains an option
for relatively healthy patients with metastatic melanoma and is still included in clinical
trials as part of combination regimens (122).
Like effector T cells, regulatory T cells (Treg) also express receptors for IL-2
(149). Because these cells are thought to suppress T cell-mediated killing and are often
found in the tumor microenvironments (TME) of patients with poor outcomes, a fusion
protein made from IL-2 and diphtheria toxin has been investigated as a method of
selectively eliminating circulating Tregs (150). Although one study reported partial
responses in 16.7% of patients treated with this fusion protein (151), another study
reported that regulatory T cells were not cleared from circulation and no objective
response was observed (152).

Immune checkpoint inhibition
T cell activation requires the presence of two stimulatory signals. The first of
these signals occurs when MHC-bound antigens on the surfaces of antigen presenting
cells (APCs) bind to T cell receptors (TCR); the second signal involves recognition of the
co-stimulatory molecules B7-1 and B7-2 (CD80 and CD86) by CD28 molecules
expressed on the membranes of T cells (153). When both signals are present, the
signaling cascade from the TCR is maximally activated, leading to production of proproliferative IL-2 and its receptor, IL-2R, as well as expression of chemokine receptors
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that enable the activated T cells to migrate towards target tissues (153). Without this
second signal, however, T cells remain in an anergic state (153).
In addition to CD28, T cells express the CD28-like proteins, cytotoxic Tlymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1), that bind costimulatory molecules with higher affinity than does CD28 (154). In contrast to CD28,
however, these molecules function to inhibit the TCR signal. When bound to B7-1 or B72 on APCs, CTLA-4 recruits the phosphatases SHP2 and PP2A, which dephosphorylate
both the T cell receptor complex and Akt, resulting in a dampening of the TCR signal
(155). The ligands for PD-1 include PD-L1 (B7-H1) and PD-L2 (B7-CD), both of which
are also expressed by APCs (156). Similar to CTLA-4, active PD-1 recruits
phosphatases SHP1 and SHP2, resulting in dephosphorylation of the T cell receptor
complex and dampening of TCR signaling (157). Interestingly, melanoma cells have
been shown to express PD-L1, which likely serves to locally inhibit the anti-tumor
immune response (158).
Whether a T cell becomes activated in the presence of an MHC-bound antigen
depends on the ratio of co-stimulatory molecules binding the lower-affinity CD28 to those
binding the higher-affinity CTLA-4 and PD-1. In the absence of local inflammation, APCs
express co-stimulatory molecules at low levels (159). In this state, they are more likely to
bind to higher-affinity CTLA-4 and PD-1, thus ensuring that T cells remain anergic and
do not attack non-inflamed, self tissues. In the presence of pathogen- and damageassociated molecular patterns (PAMPs and DAMPs), however, pattern recognition
receptors such as toll-like receptors (TLRs) are stimulated, leading to upregulation of costimulatory molecules (159). In this state, co-stimulatory molecules are more likely to
bind to lower-affinity CD28, allowing for TCR signaling to proceed. This is a critical
“immune checkpoint” that functions to ensure that T cells become active only in the
presence of a pathogen or other source of tissue damage (159).
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Due to their pivotal role in regulating whether T cells are able to respond to
antigens, CTLA-4, PD-1, and PD-L1 are attractive targets for immunotherapy. The
relatively new class of immunotherapies known as immune checkpoint inhibitors function
to inhibit these molecules, thereby disinhibiting T cell activation (154). The first of these
therapies, ipilimumab, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody
directed against CTLA-4 that prevents it from binding B7-1/B7-2 (160). It was approved
for treatment of metastatic melanoma in 2011 after clinical trials demonstrated a median
overall survival of 10.1 months with ipilimumab monotherapy (161) and of 11.2 months
when combined with dacarbazine (162). Responses are seen in up to 19% of patients,
and median progression-free survival is 2.9 months, which is increased from that of
chemotherapy. Furthermore, responses to ipilimumab are durable in a significant
number of patients, with 4-year overall survival ranging from 13.8% to 49.5% (163).
Apart from ipilimumab, another antibody targeting CTLA-4, tremelimumab, is currently
being assessed in clinical trials, although it has yet to show improvement in overall
survival (164).
Nivolumab is a humanized IgG4 monoclonal antibody directed against PD-1 that
inhibits co-stimulatory molecules from binding to PD-1 (165). Approved for treatment of
metastatic melanoma in 2014, nivolumab therapy has a 40% response rate and median
progression-free survival of 6.9 months, longer than that of both ipilimumab therapy and
chemotherapy (166). This increases to 11.5 months when nivolumab is combined with
ipilimumab; such a combination is particularly beneficial to patients whose tumors do not
express PD-L1 (166). Another anti-PD-1 antibody, pembrolizumab, was approved in
2015, and has been shown to produce a 46-48% six-month progression-free survival
rate, a 68-75% one-year overall survival rate, and a 32-34% response rate as compared
to a 26.5% six-month progression-free survival rate, a 58.2% one-year overall survival
rate, and a 19% response rate with ipilimumab therapy (167). In addition to antibodies
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targeting PD-1, anti-PD-L1 therapies such as atezolizumab, avelumab, and darvalumab
are currently being assessed for efficacy against metastatic melanoma (122).
The effects of immune checkpoint inhibition are not limited to malignant tissues,
however. Immune activation is often nonspecific, and autoimmune toxicities, or irAEs,
commonly affect patients on these regimens (160, 168). High grade toxicities that
require temporary or permanent cessation of immune checkpoint inhibitor therapy have
been seen in approximately 27% of patients treated with ipilimumab monotherapy, the
most common of which are dermatitis, enterocolitis, endocrinopathy, and hepatotoxicity
(8). Similar toxicities are seen in 10-15% of patients treated with PD-1 or PD-L1
inhibitors and in 55% of patients treated with a combination of ipilimumab and nivolumab
(8). PD-1 inhibitors, in particular, have been associated with severe pneumonitis that has
been fatal in rare cases (165). In addition, fulminant myocarditis, brittle diabetes, and
severe neurologic disorders such as multiple sclerosis, Guillain-Barre Syndrome, and
myasthenia gravis have all been described in patients receiving immune checkpoint
inhibitor therapy (169). Interestingly, studies have shown that an anti-tumor immune
response is more likely to occur in patients that develop irAEs (170).
The treatment of an irAE depends upon its severity. Low-grade toxicities are
typically managed with corticosteroids and symptom control while high-grade and lifethreatening toxicities require systemic corticosteroids and changes to the
immunotherapy regimen (8). While most irAEs respond to corticosteroids, some are
refractory and require additional immune suppression (8). With this in mind, it is
important to understand the mechanisms by which different irAEs occur. Although most
irAEs are considered to be off-target effects of T cell activation, B cell-mediated
autoantibody secretion has been linked to some toxicities, including autoimmune
hemolytic anemia and bullous lichenoid dermatitis (171). Chapter two will discuss an
experiment in which we utilized our melanoma model to determine whether treating such
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irAEs with therapies that deplete B cells would hinder the anti-tumor effects of anti-PD-1
therapy. Such experiments will be important as the use of immune checkpoint inhibitors
continues to expand.

Adoptive cell therapy
Another approach to accessing the anti-tumor potential of T cells is called
adoptive cell therapy. This process involves the in vitro expansion of TILs derived from a
resected melanoma and the subsequent infusion of these cells back into the patient
(172). The success of this approach hinges on a brief in vitro expansion phase and
depletion of host lymphocytes prior to infusion. Such depletion is thought to reduce
competition for pro-proliferative cytokines such as IL-7 and eliminate suppressive Tregs
from the circulation (172). Clinical trials of adoptive cell therapy paired with harsh
lymphocyte depletion regimens including cyclophosphamide, fludarabine, and total body
irradiation reported objective response rates of up to 72% and durable complete
responses in 10-20% of patients (173). Toxicities of the lymphodepletion regimen were
common and severe, however, and more recent protocols have accepted somewhat
lower objective response rates of 40-50% in order to avoid total body irradiation (174).
An alternative to traditional adoptive cell therapy involves infusing patients with
genetically engineered T cells that express tumor-specific receptors called chimeric
antigen receptors (CAR) (175). These receptors are formed by genetically fusing
variable regions of tumor antigen-specific antibodies to a transmembrane domain that
interacts with the T cell receptor complex (176). The resulting CAR genes are
transferred into T cells using a retroviral or lentiviral vector, and the CAR-TCR is
expressed, thus forming CAR-T cells. Although this approach has not yet been approved
for melanoma, several clinical trials are in process (122).
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Other immunotherapies
Although immune checkpoint inhibitors are the current drugs of choice for
patients with metastatic melanoma, research into melanoma immunology continues to
expand, inspiring novel immunotherapies in the process. One example, a genetically
modified herpes virus called talimogene laherparepvec (T-VEC), was approved in 2015
for the treatment of unresectable and metastatic melanoma (177). This lytic virus is
injected directly into melanoma tumors and replicates only in malignant cells, leading to
rupture of tumor membranes and leakage of melanoma antigens into the surrounding
tissue; APCs present these antigens and proceed to activate T cells (177). Early-phase
clinical trials with T-VEC have shown a 28% objective response, and other trials are
ongoing (178).
Another novel therapy approach involves vaccinating patients with gp100, a
glycoprotein expressed by melanoma cells and recognized by TILs (179). Although
vaccination alone did not produce benefits in preclinical models, combination therapy
with IL-2 improved progression-free-survival, median overall survival, and complete
response rate when compared to IL-2 monotherapy (180).

Conclusion
There has been an immense amount of progress in the field of metastatic
melanoma treatment since the days when dacarbazine was the most promising option
for patients. The fact that immune checkpoint inhibitors have produced durable,
complete responses in a subset of patients and are now considered first-line therapy for
metastatic melanoma underscores their profound impact on the treatment landscape.
Despite these successes, however, both primary and acquired resistance limit many
patients from realizing the benefits of immune checkpoint inhibitor therapy. For this
reason, there is continued need for research into the precise mechanisms used by these
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medications as well as the mechanisms by which they fail. Because addressing many of
the questions that underlie these aims would be infeasible in humans, high-quality
animal models that recapitulate the properties of human melanoma are necessary. The
following section will detail the development and characteristics of such a model that
was engineered to reflect the genetic mutations and immunogenicity observed in human
melanomas.
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C. The Yale University Mouse Melanoma Model
Much of what is currently known about melanoma was discovered using murine
models. The most widely used model, B16, was derived from a melanoma that arose
spontaneously in an inbred C57Bl/6J mouse. Developed by Harold E. Harding and R. D.
Passey in 1930, it has since been employed to study both basic melanoma biology and
anti-tumor immune responses. Despite its utility, however, four important limitations
restrict its ability to generate translatable findings, particularly within the scope of
melanoma immunology. First, in contrast to human melanomas, retroviral elements in
the B16 genome have been shown to play an important role in tumorigenesis (181).
Second, it is a unique line without obvious analogs, thereby making validation
experiments difficult. Third, the driver mutations that contribute to tumor formation in the
B16 model are unknown, and as a consequence, it is difficult to assess the effects of
specific melanoma genotypes using the model. Fourth and perhaps most important, B16
melanomas grow rapidly and express low levels of MHC Class I molecules, thereby
restricting their immunogenicity (182).
With these limitations in mind, several groups have set out to develop
genetically-engineered mouse models (GEMM) to better recapitulate human
melanomas. The first such GEMM of melanoma was a BRAFV600E/PTEN-/- mouse model
first described in 2009 (183). To generate this model, mice heterozygous for a Crerecombinase-dependent BRAFV600E allele and homozygous for a floxed PTEN allele
were crossed with mice harboring melanocyte-restricted estrogen-receptor-linked Cre
recombinase under the control of the Tyrosinase promoter; the resulting Tyr::CreER;
BRAFCre-dependent V600E/+; PTENlox/lox offspring rapidly and reliably develop melanomas at
the sites of topical 4-hydroxytamoxifen administration (183).
Additional GEMMs have since been created using similar techniques, allowing
for several of the common genetic signatures discussed in chapter 1A to be studied in
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mouse melanoma models. A major drawback to these GEMMs, however, is the difficulty
inherent to maintaining the mouse colonies required to produce offspring with the target
genotypes (181). To address this, the Bosenberg lab set out to generate a library of
GEMM-derived cell lines that would reliably grow tumors when grafted into
immunocompetent C57Bl/6J mice. Meeth, et al. backcrossed several relevant alleles to
C57Bl/6J mice and subsequently interbred the resulting mice to create inducible models
of several melanoma genotypes. Melanomas were induced on these mice using 4hydroxytamoxifen, and cell lines were generated from resulting tumors using a standard
protocol (Figure 1C.1). Collectively, these cell lines are known as the Yale University
Mouse Melanoma (YUMM) lines (181) and represent the majority of documented
melanoma genotypes including BRAF-mutant, NRAS-mutant, and BRAF/NRAS/NF-1
wildtype (Figure 1C.2). As discussed in chapter 1A, gain-of-function mutations in BRAF
are often accompanied by loss-of-function mutations in either PTEN or CDKN2A,
allowing cells to overcome oncogene-induced senescence; this is reflected in the YUMM
lines.

Figure 1C.1: Flowchart depicting melanoma induction and YUMM line generation.
Adapted from “The YUMM lines: a series of congenic mouse melanoma cell lines with
defined alterations” by Meeth, et al. (2016). PMC5331933.
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Name

Genotype

YUMM1

BrafV600EPten-/- Cdkn2a-/-

YUMM2

BrafV600EPten-/- Bcatsta/+

YUMM3

BrafV600ECdkn2a-/-

YUMM4

Pten-/- Cdkn2a-/-

YUMM5

BrafV600E p53-/-

YUMM6

BrafV600EPten-/-

YUMM7

BrafV600EBcatsta/+Cdkn2a-/-

YUMM8

BrafV600ELkb1-/-Cdkn2a-/-

YUMM9

NrasQ61R Cdkn2a-/-

YUMM10

NrasQ61R p53-/-

Figure 1C.2: Driver mutations in various YUMM lines.
Tumors grown from injected YUMM cells grew significantly faster than those
induced on their corresponding GEMMs, reaching a volume of 1 cm3 within seven weeks
(Figure 1C.3). Despite this difference in growth rate, YUMM tumors were histologically
similar to their corresponding GEMM tumors, providing reassurance that genetic drift
had not played a significant role during production of the cell lines. Additionally, BRAFmutant YUMM tumors were shown to exhibit a pattern of initial vemurafenib sensitivity
followed by acquired resistance in vivo (Figure 1C.4), thereby mimicking the behavior of
human melanomas (181).
Like B16 melanomas, however, YUMM melanomas are poorly immunogenic.
When YUMM1.7 cells (a specific line with the YUMM1 genotype) were injected into both
wildtype and RAG1-/- mice that are deficient in T and B cells due to loss of somatic
recombination, tumors grew at a similar rate, suggesting that a functional adaptive
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immune system does not hinder YUMM cell growth (Figure 1C.5A).
Immunohistochemical examination of YUMM tumors grown in immunocompetent mice
revealed that approximately 40% of nucleated cells within tumors were CD45+
leukocytes, the majority of which were F4/80+ tumor-associated macrophages; less than
1% of these leukocytes were CD3+ T cells (Figure 1C.5B) (181).

Figure 1C.3: Growth rate of YUMM tumors. YUMM cells injected into C57Bl/6J mice
form 1 cm3 tumors within 7 weeks. Adapted from “The YUMM lines: a series of congenic
mouse melanoma cell lines with defined alterations” by Meeth, et al. (2016).
PMC5331933.

Figure 1C.4: YUMM tumors treated with BRAF inhibitors. YUMM tumors are initially
sensitive to BRAF inhibition (left) but develop resistance after prolonged exposure
(right). PLX4720 is a BRAF inhibitor. Adapted from “The YUMM lines: a series of
congenic mouse melanoma cell lines with defined alterations” by Meeth, et al. (2016).
PMC5331933.
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Figure 1C.5: YUMM1.7 tumors are poorly immunogenic. A. YUMM1.7 tumors grow at
a similar rate regardless of adaptive immune function. B. Lymphocytes comprise a
minority of intratumoral leukocytes in YUMM tumors. Adapted from “The YUMM lines: a
series of congenic mouse melanoma cell lines with defined alterations” by Meeth, et al.
(2016). PMC5331933.
The YUMM lines harbor the driver mutations, but not the significant “passenger”
mutation burden, characteristic of human melanomas (17). As previously discussed,
melanomas are among the most somatically mutated tumors, with an average mutation
rate of 16.8 mutations per megabase per exome observed in tumors analyzed by TCGA
(21). These mutations are largely consistent with ultraviolet signature and do not appear
to influence the growth or mitotic behavior of cells (184). They are, however, thought to
encode “neoantigenic” peptides that increase the immune recognition of melanoma cells
through presentation on MHC Class I molecules. This is supported by the observation
that high somatic mutation burden is positively correlated with responsiveness to
immune checkpoint inhibitor therapy (185, 186).
In order to better recapitulate the immunogenicity of human melanomas, the
Bosenberg lab next sought to increase the somatic mutation burden of YUMM cells
(187). YUMM1.7 cells in culture were irradiated with three rounds of 1500J/m2 UV-B
light, and a single irradiated cell was clonally expanded, giving rise to a new cell line
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known as YUMM Exposed to Radiation-1.7, or YUMMER1.7 (Figure 1C.6). Whole
exome sequencing of YUMMER1.7 cells demonstrated 1446 unique mutations not
present in the parental YUMM1.7 line, 81.5% of which were C-to-T transitions consistent
with UV-B exposure; these mutations were stable through multiple cell passages.

Figure 1C.6: Development of the YUMMER1.7 line. To generate YUMMER1.7 cells,
YUMM1.7 cells were irradiated with three rounds of UV-B, and a clone was derived from
a single irradiated cell.
Injections of 100,000 YUMMER1.7 cells were administered to the flanks of
immunocompetent and RAG-/- C57Bl/6J mice, and tumor volume measurements were
obtained. In 80% of immunocompetent mice, a “spontaneous regression” phenotype was
observed, in which tumors initially grew before regressing completely (Figure 1C.7).
Even higher rates of spontaneous regression were seen when fewer than 100,000 cells
were injected. In all RAG-/- mice, however, tumors grew at a rate similar to that observed
with YUMM1.7 injection, thus demonstrating that spontaneous regression is mediated by
lymphocytes. Further experiments showed that spontaneous regression is lost with
antibody-mediated depletion of both CD4+ and CD8+ T lymphocytes, indicating that the
phenotype is T cell-dependent (Figure 1C.8). Interestingly, there appears to be a
threshold above which the immune system is unable to contain tumor growth, as
injections of greater than 250,000 YUMMER1.7 cells produce tumors in both
immunocompetent and immunodeficient mice (Figure 1C.9).
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Figure 1C.7: Spontaneous regression with YUMMER1.7. YUMMER1.7 tumors
regress following an initial growth phase in wildtype mice (left). Regression does not
occur in immunodeficient mice (right). Adapted from “UV-induced somatic mutations
elicit a functional T cell response in the YUMMER1.7 mouse melanoma model” by
Wang, et al. (2017). PMC5820096.

Figure 1C.8: Spontaneous regression is T cell-dependent. T cell depletion eliminates
the spontaneous regression phenotype. Adapted from “UV-induced somatic mutations
elicit a functional T cell response in the YUMMER1.7 mouse melanoma model” by
Wang, et al. (2017). PMC5820096.

Figure 1C.9: Tumor formation with YUMMER1.7. Spontaneous regression does not
occur with injections of 250,000 of more cells. Adapted from “UV-induced somatic
mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma
model” by Wang, et al. (2017). PMC5820096.
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A key property of the adaptive immune system is the development of memory
cells that recognize and swiftly eliminate previously encountered antigens. Given that
spontaneous regression of YUMMER1.7 tumors was determined to be T cell-dependent,
it was hypothesized that YUMMER1.7 cells injected following a spontaneous regression
would be promptly rejected. To test this, C57Bl/6J mice that had successfully rejected
injections of 100,000 YUMMER1.7 cells were rechallenged with 500,000-cell injections
to their opposite flanks. Tumor growth was not observed in any of these rechallenged
mice, a result that starkly contrasts the robust tumor growth seen when naïve mice are
injected with 500,000 YUMMER1.7 cells. This memory response was T cell-dependent,
as it disappeared with antibody-mediated depletion of CD4+ and CD8+ T lymphocytes
(187).
To further investigate the immune infiltrate in YUMMER1.7 tumors, GFP-labeled
YUMMER1.7 cells were injected into mice, and tumors were harvested at various time
points. CD45+ and CD3+ infiltrates increased over time in regressing tumors formed
from 100,000-cell injections while remaining relatively steady in escaping tumors formed
from 500,000-cell injections (Figure 1C.10). Cleaved caspase-3, a marker of apoptosis,
was also shown to increase as tumors regressed. Additionally, the ratio of Foxp3+ Tregs
to total CD3+ T cells remained relatively low in regressing tumors while it increased in
escaping tumors (Figure 1C.11). As a control, GFP-labeled YUMM1.7 cells were injected
into mice, resulting in tumor formation in all cases. Compared to escaping YUMMER1.7
tumors, YUMM1.7 tumors contained significantly less CD3+ infiltration, suggesting that
the immune system recognizes but fails to contain escaping YUMMER1.7 tumors (187).
The reason for this failure is of great interest to basic science researchers and
clinicians alike, as clinically significant melanomas have, by definition, escaped immune
control. One theory is that immunosuppressive elements in the tumor microenvironment
including Tregs and myeloid-derived suppressor cells (MDSC) produce signals that deter
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T cells from entering tumors and killing malignant cells. This is supported by the
observation that Tregs comprise an increasing proportion of all TILs as YUMMER1.7
tumors grow out (Figure 1C.11) (187). Another theory is that prolonged exposure to
tumor antigens in the absence of strong co-stimulatory signals may induce T cells to
adopt an exhausted phenotype, as has been observed in chronic viral infections (188).
Chapter four will discuss several experiments intended to gauge whether this occurs.
Finally, it is possible that the increased overall mitotic rate that characterizes higher
inoculation numbers overwhelms the immune system’s capacity to recognize and kill
tumor cells.

Figure 1C.10: Immune infiltration in YUMMER1.7 tumors. YUMMER1.7 tumors
formed from 100,000-cell injections (left) exhibit increasing CD45+, CD3+, and F4/80+
infiltrates as they regress. YUMMER1.7 tumors formed from 500,000-cell injections
(right) exhibit relatively stable CD45+, CD3+, and F4/80+ infiltrates and eventually grow
out. Adapted from “UV-induced somatic mutations elicit a functional T cell response in
the YUMMER1.7 mouse melanoma model” by Wang, et al. (2017). PMC5820096.
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Figure 1C.11: Tregs in YUMMER1.7 tumors. YUMMER1.7 tumors formed from
100,000-cell injections (left) exhibit a relatively stable ratio of Tregs to T cells.
YUMMER1.7 tumors formed from 500,000-cell injections (right) exhibit an increasing
ratio of Tregs to T cells as they grow out. Adapted from “UV-induced somatic mutations
elicit a functional T cell response in the YUMMER1.7 mouse melanoma model” by
Wang, et al. (2017). PMC5820096.
Regardless of the specific mechanism or mechanisms by which large inocula of
YUMMER1.7 cells escape immune control, the injection of 500,000 YUMMER1.7 cells
provides an ideal model with which to study immune therapies. Wang, et al. showed that
while 100% of isotype control-treated tumors progressed to an endpoint of 1 cm3 volume
by day 32 post-injection, 80% of anti-CTLA-4-treated tumors, 40% of anti-PD-1-treated
tumors, and 100% of dual anti-CTLA-4/anti-PD-1-treated tumors regressed completely
and did not return during an observation period of 180 days (Figures 1C.12 and 1C.13).
Tumor growth was significantly delayed in the few tumors that did progress on
immunotherapy. These results were validated in repeat experiments, and checkpoint
blockade was found to be most effective when started on post-injection day 7 and
administered every other day for three weeks. In contrast to immunogenic YUMMER1.7
tumors, YUMM1.7 tumors are insensitive to immune checkpoint blockade and reach
endpoint by 45 days post-injection (Figure 1C.12) (187).
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Figure 1C.12: YUMMER1.7 tumors are sensitive to immune checkpoint inhibitors.
Survival curves comparing mice bearing YUMMER1.7 tumors (left) or YUMM1.7 tumors
(right) treated with either immune checkpoint inhibitors or isotype control. Adapted from
“UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7
mouse melanoma model” by Wang, et al. (2017). PMC5820096.

Figure 1C.13: YUMMER1.7 tumors are sensitive to immune checkpoint inhibitors.
Spider plots comparing growth of YUMMER1.7 tumors treated with anti-CTLA-4 (top
left), anti-PD-1 (top right) or both (bottom) to untreated tumors. Adapted from “UVinduced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse
melanoma model” by Wang, et al. (2017). PMC5820096.
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Conclusion
The recent proliferation of genetic technologies has provided researchers with
the ability to design melanoma GEMMs that harbor the clinically relevant driver
mutations discussed in chapter 1A. Tumors derived from these GEMMs are more similar
to human melanomas than are B16 melanomas, thereby increasing the likelihood that
experimental results will translate to the clinic. The YUMM lines are a series of
syngeneic melanoma cell lines derived from C57Bl/6J GEMMs that collectively represent
the known genetic subsets of melanoma. When injected, these cells form tumors in
C57Bl/6J mice that are initially sensitive to targeted therapy but develop resistance after
a period of exposure. They are poorly immunogenic, however, and do not respond to
immune checkpoint inhibitors. To increase their immunogenicity, YUMM1.7 cells were
irradiated with ultraviolet light to increase their somatic mutation burden. The resulting
YUMMER1.7 cells exhibit several important growth characteristics. First, tumors formed
from small numbers of YUMMER1.7 cells (<100,000) spontaneously regress in a T celldependent fashion. Second, tumors formed from large numbers of YUMMER1.7 cells
(>250,000) uniformly grow out despite exhibiting T cell infiltration. Third, treatment with
immune checkpoint inhibitors allows for complete and durable regression in a subset of
these high-inoculum tumors. These properties of YUMMER1.7 cells make them an
attractive model with which to study basic melanoma immunology as well as
immunotherapy.
With this in mind, the following three chapters will discuss experiments
conducted in the Bosenberg lab using the YUMMER lines. Chapter two will explore the
role of B lymphocytes in the anti-tumor immune response and the potential for B cell
depletion as treatment for certain irAEs. Next, chapter three will discuss whether
manipulation of myeloid cells in the tumor microenvironment can convert immuneresistant tumors into immune-sensitive tumors. Finally, chapter four will describe

38
experiments aiming to compare and contrast the T cell phenotypes involved in
successful and failed anti-tumor immune responses. Unless otherwise noted, the
following chapters represent work performed by the author.
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Chapter Two: The Impact of B Cell Depletion on Anti-PD-1 Efficacy
This section was written in collaboration with Wiliam Damsky, MD, PhD and Harriet
Kluger, MD.

Background and Hypothesis
The list of approved indications for immune checkpoint inhibitors continues to
expand as clinical trials report survival benefits in patients with a variety of malignancies.
In addition to melanoma, checkpoint inhibition has been approved to treat renal cell
carcinoma, non-small cell lung cancer, urothelial carcinoma, cervical cancer,
hepatocellular carcinoma, head and neck cancer, colon cancer with microsatellite
instability, Hodgkin’s lymphoma, Merkel cell carcinoma, and urothelial carcinoma (189199). The excitement surrounding the benefits of these medications is somewhat offset,
however, by the immune-mediated toxicities (irAEs) experienced by a large number of
patients on these therapies. As discussed in chapter 1B, these irAEs can affect almost
any organ system and range in severity from mild to life-threatening. Many of these
toxicities are thought to result from off-target T cell activation, and they often resolve with
the administration of corticosteroids or TNF-α inhibitors (8). Some irAEs, however, may
be mediated or exacerbated by B cells. Indeed, there are case reports of steroidrefractory irAEs that resolved following administration of rituximab, an anti-CD20
antibody that depletes B cells (Figure 2.1) (171, 200-203). While retrospective analyses
have indicated that neither steroids nor TNF-α inhibitors interfere with the anti-tumor
immune reponse induced by immune checkpoint inhibitors, little is known about the
impact of B cell depletion on this response (8, 204). To explore this question, we first
used the YUMMER1.7 murine melanoma and MC38 murine colon carcinoma models to
compare responses to anti-PD-1 therapy in the presence and absence of B cells. We
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then compared B cell infiltration in anti-PD-1-responsive and anti-PD-1-nonresponsive
human melanoma samples. We hypothesized that B cells are nonessential to the antitumor immune response, and for this reason, their depletion would have little to no
impact on the effects of PD-1 inhibitors.

Figure 2.1: Reports of rituximab use in treatment of irAEs. ITP, immune
thrombocytopenic purpura; PR, partial response; CR, complete response; PD,
progressive disease; SD, stable disease; NR, not reported.
Methods
Cell lines and tissue culture
The YUMMER1.7 melanoma model was described in chapter 1C. The MC38
model is a syngeneic colon cancer cell line that produces immunogenic tumors when
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injected into C57Bl/6J mice (206). All cell lines were maintained in DMEM/F12 media
containing 10% FBS, 1% nonessential amino acids, and 1% penicillin-streptomycin.

Murine models
YUMMER1.7 and MC38 tumor cells were implanted subcutaneously into the right
hind flanks of wildtype C57Bl/6J mice, muMT (Ighm-/-) mice deficient in B cells, and
Rag1-/- mice deficient in both B and T cells, all from Jackson Laboratory. To form
YUMMER1.7 tumors, 500,000 cells were implanted as described in chapter 1C. For
spontaneous regression of YUMMER1.7 tumors, 100,000 cells were implanted as
described in chapter 1C. To form MC38 tumors, 250,000 cells were implanted. Mice
were euthanized according to humane endpoints when tumors reached 1.5 cm in
maximum dimension or when tumors ulcerated.

Drug treatments
Treatment with RMP1-14, an anti-mouse PD-1 antibody from Bio X Cell, was
initiated on post-injection day 7 when tumors were roughly 50-100 mm3 in size. Anti-PD1 was diluted in sterile saline and administered by intraperitoneal injection at a dose of 8
mg/kg every 3 days for a total of 6 doses. Treatment with AISB12, an anti-mouse CD20
antibody from Bio X Cell, was initiated on post-injection day 9 (3 days following initiation
of anti-PD-1 therapy) and administered at a dose of 25 mg/kg in sterile saline by
intraperitoneal injection on two consecutive days. Anti-CD20 therapy was similarly
repeated every 2 weeks. Saline vehicle was administered to control animals.

Immunohistochemistry
At experimental endpoint, murine tumors were harvested, formalin-fixed, and
paraffin-embedded using standard methods. Immunohistochemistry using anti-mouse
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B220 antibody to identify CD45R (PTPRC) on the surface of B cells was performed
using standard methods. The intratumoral B cell density (number of B220-positive cells
per high power field) was assessed for 10 HPF per tumor, and the mean was calculated
using 3 replicate animals per group. This was performed with the assistance of William
Damsky, MD, PhD and Marcus Bosenberg, MD, PhD.

Tumor dissociation and flow cytometry
Tumors were minced in RPMI medium with 2% fetal bovine serum (FBS), 0.5
mg/mL collagenase IV, and 200 mg/L DNase. They were then digested in a 37C
incubator for 30 min and filtered to remove debris. Single-cell suspensions from tumors
or splenocytes were incubated on ice for 15 minutes with 2.4G2, an anti-Fc receptor
antibody. The cells were then stained with appropriate antibodies in 2.4G2-containing
buffer. Data was acquired on an LSR II (BD Biosciences) and analyzed with FlowJo.
LIVE/DEAD discrimination was performed using the LIVE/DEAD Fixable Red Dead Cell
Stain Kit from Invitrogen. Antibodies against CD45 (A20) were obtained from
eBioscience. Antibodies against CD3 (17A2), CD11b (M1/70) and CD20 (SA275A11)
were obtained from Biolegend. Antibodies against B220 (RA3-6B2) were obtained from
BD Biosciences. These steps were performed by William Damsky, MD, PhD and Curtis
Perry, MD, PhD.

Patients
Tumor samples from 40 patients with advanced melanoma treated with PD-1
inhibitors were analyzed, of which 34 were evaluable for response. Areas of invasive
melanoma were identified and cored by a board-certified pathologist. A tissue microarray
(TMA) was generated using methods that have been previously described, incorporating
three cores per specimen (207, 208). Specimens and clinical information were retrieved
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with approval of the Yale University Human Investigations Committee. Patient
demographics are summarized in Figure 2.2. The cohort included 70% males and 30%
females. Age at initiation of therapy ranged from 43 to 92 with a mean of 66. At the start
of therapy, 5% had stage M1a disease, 15% had stage M1b disease, and 80% had
stage M1c disease. LDH was elevated in 35% of patients; BRAF, NRAS, and KIT
mutations were found in 30%, 25%, and 5% of cases, respectively. 77.5% of patients
had cutaneous non-acral lentiginous melanoma, 10% had acral melanoma, 10% had
mucosal melanoma, and 2.5% had uveal melanoma. RECIST 1.1 criteria were used for
clinical assessment and classification of response. This was performed by Harriet
Kluger, MD and Lucia Jilaveanu, MD, PhD.
Characteristic
Age, years
Median
Range
Sex
Male
Female
Elevated LDH
Mutation
BRAF
NRAS
KIT
GNAQ
Primary melanoma type
Cutaneous non-acral lentiginous
Acral
Mucosal
Uveal

n

%
66
43-92

28
12
14

70
30
35

12
10
2
1

30
25
5
0.25

31
4
4
1

77.5
10
10
2.5

Figure 2.2: Baseline characteristics of melanoma patients treated with anti-PD-1
therapy (N=40).
Immunofluorescence staining and quantification of B cell content
Immunofluorescence staining was performed using standard methods (209, 210).
Staining for CD20 was performed with a mouse monoclonal antibody (clone L26) from
Dako. Tumor area was identified with a rabbit anti-S100 antibody from Dako. To
determine the degree of tumor-infiltrating B cells, CD20-positive cells within the tumor
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mask were counted within each histospot. Tumor spots were included if they contained
sufficient tissue for analysis (>3% of the histospot area) and did not contain abundant
necrotic tissue. This was performed by Lucia Jilaveanu, MD, PhD.

Statistical analyses
For murine data, Prism version 7.0 software was used. Difference in survival was
assessed using the Kaplan-Meier method, and statistical significance was determined
using the log-rank (Mantel-Cox) test. For human data, JMP version 5.0 software was
used (SAS Institute, Cary, NC). The association between B cell content and objective
response status (complete or partial response vs. stable or progressive disease) was
assessed using t-tests. Survival curves were constructed using the Kaplan-Meier
method, and statistical significance was determined using the log-rank test.

Results
To determine whether B cell depletion with anti-CD20 antibodies affects the antitumor efficacy of PD-1 inhibitors, we used the MC38 colon carcinoma and YUMMER1.7
melanoma models. We first characterized baseline intratumoral B cell infiltration using
B220 immunohistochemistry and found that B cells were present in both models. In
YUMMER1.7 tumors, B cells tended to cluster in aggregates at the edges, whereas B
cells were distributed fairly evenly throughout MC38 tumors (Figure 2.3A-D).
40 mice with established MC38 tumors were divided into four treatment groups
with 10 mice per group: control, anti-CD20 alone, anti-PD-1 alone, and anti-CD20 + antiPD-1. They began receiving anti-PD-1 therapy on post-injection day 7, followed 2 days
later by anti-CD20 therapy with AISB12, an antibody that has been shown to effectively
deplete murine B cells in blood, spleen, bone marrow and other tissues (211-213). As
shown in the Kaplan-Meier curves in Figure 2.4A, survival did not differ when anti-CD20
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antibodies were added to anti-PD-1 therapy. Moreover, survival did not differ between
mice treated with anti-CD20 antibodies alone and control mice, further supporting the
hypothesis that B cells are not required for effective anti-tumor immune responses
induced by PD-1 inhibition. Tumor volumes for these four cohorts of mice are shown by
waterfall plots in Figure 2.4B and spider plots in Figure 2.5A.
Another 40 mice with established YUMMER1.7 tumors were divided into the
same four treatment groups used in the previous experiment. As with the MC38
experiment, we showed that anti-CD20 antibodies neither affect tumor growth or survival
nor impair the anti-tumor effect induced by PD-1 inhibitors (Figures 2.4C, 2.4D, and
2.5B). As shown in Figures 2.3E and 2.3F, anti-CD20 antibodies were effective in
reducing B cell infiltrate in both tumor and spleen. Importantly, there were no signs of
distress in any of the animals treated with anti-CD20 antibodies; weight and activity
levels were maintained throughout the experiment.
To further test the hypothesis that B cell activity is dispensable for effective antitumor immune responses induced by PD-1 inhibition, we employed muMT mice that lack
B cells due to biallelic inactivation of the Ighm gene that encodes the IgM heavy chain
(214). We first tested the ability of muMT mice to spontaneously reject YUMMER1.7
cells as described in chapter 1C. When 100,000 YUMMER1.7 cells were injected into
muMT host animals, they were able to reject YUMMER1.7 cells as efficiently as
C57Bl/6J control animals. Rag1-/- mice were also included as controls and failed to reject
100,000-cell injections (Figure 2.6A). We then assessed the effect of B cell deficiency in
the setting of immunotherapy by treating both wildtype and muMT mice bearing MC38
tumors with PD-1 inhibitors. There was no difference in survival between these groups
(Figure 2.6B). Taken together, these data suggest that while T cells are required for
immune-mediated rejection of YUMMER1.7 tumors, B cells are not.
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Figure 2.3: B cells in MC38 and YUMMER1.7 tumors. A. Tumor-infiltrating B cell
density in MC38 tumors. B. Quantification of A. C. Tumor-infiltrating B cell density in
YUMMER1.7 tumors. D. Quantification of C. E. Quantification of flow cytometry
experiments showing number of CD20+ cells in spleen (shown as percentage of all
lymphocytes). F. Quantification of flow cytometry experiments showing number of
CD20+ cells in tumor (shown as percentage of all lymphocytes).
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Figure 2.4: Anti-CD20 antibody therapy does not affect anti-tumor immune
responses in murine models of colon cancer (MC38) and melanoma (YUMMER1.7).
A. Survival of MC38 tumor-bearing mice treated with saline (ctrl), anti-CD20, anti-PD-1,
or anti-CD20 + anti-PD-1 (comb). Ctrl vs. CD20 p=0.78; PD-1 vs. comb p=0.67; ctrl +
comb p<0.0001. B. Waterfall plot of groups in A. C. Survival of YUMMER1.7 tumorbearing mice treated with saline (ctrl), anti-CD20, anti-PD-1, or anti-CD20 + anti-PD-1
(comb). Ctrl vs. CD20 p=0.08; PD-1 vs. comb p=0.73; ctrl + comb p=0.0008. D. Waterfall
plot of groups in C.
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Figure 2.5: Anti-CD20 antibody therapy does not affect anti-tumor immune
responses in murine models of colon cancer (MC38) and melanoma (YUMMER1.7).
A. Spider plots showing MC38 tumor growth in individual mice from Figures 2.4A and
2.4B. B. Spider plots showing YUMMER1.7 tumor growth in individual mice from Figures
2.4C and 2.4D.
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Figure 2.6: B cell deficiency does not impair anti-tumor immune responses in
murine models of colon cancer (MC38) and melanoma (YUMMER1.7). A. Survival of
mice after implantation of 100,000 YUMMER1.7 cells. C57Bl/6J (B6) vs. muMT
p=0.7319. muMT vs. Rag1-/- p<0.0001. B. Survival of MC38 tumor-bearing mice treated
with anti-PD-1. C57Bl/6J (B6) vs. muMT p=0.1435.
Tumor samples from 40 melanoma patients were analyzed, and B cells were
quantified in each. Tumor-infiltrating B cells were fairly sparse in most samples, ranging
from 0-131 cells per 0.6 mm histospot with a median of 2.5 B cells and a mean of 17.4 B
cells. Examples of heavily and poorly infiltrated tumors are shown in Figure 2.7 A and B,
respectively. 34 of the 40 patients in this cohort were evaluable for response, and the
objective response rate to PD-1 inhibitors by RECIST1.1 criteria was 32%. As shown in
Figure 2.8A, there was no association between B cell content and response. Using the
Cox Proportional Hazards method, we found no association between B cell content and
progression-free or overall survival (p=0.18 and p=0.64, respectively). We categorized
tumors as B cell-rich or B cell-poor based on whether their B cell content was greater
than or less than the median and found no significant difference in progression-free
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survival (P=0.18) or overall survival (P=0.64) among the groups by log rank statistics
(Figure 2.8B-C).

Figure 2.7. Examples of B cell-rich (A) and B cell-poor (B) tumors. Tumor is masked
by a cocktail of antibodies to S100 and HMB45 conjugated to Cy2 (green), and the area
of B cell infiltrate is determined by the relative area of CD20-positive cells within the
tumor mask, identified by anti-CD20 antibodies conjugated to Cy5 (red). Nuclei are
identified by DAPI (blue).

Figure 2.8. Tumor-infiltrating B cell density is not associated with response to
anti-PD1 therapy. A. B cell quantification in responders (CR: complete response, PR:
partial response) (n=11) vs. non-responders (SD: stable disease, PD: progressive
disease) (n=23), p=0.22. B. Presence or absence or tumor-infiltrating B cells does not
correlate with progression free survival, p=0.18. C. Presence or absence of tumorinfiltrating B cells does not correlate with overall survival, p=0.64.
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Discussion
We utilized two murine models to determine the effect of B cell-depleting
antibodies on tumor control in the setting of PD-1 inhibition and showed that the addition
of antibodies targeting CD20 to anti-PD-1 therapy has no effect on tumor growth or
animal survival. We additionally showed that mice deficient in B cells neither exhibited a
defect in spontaneous immune-mediated tumor rejection nor a defect in anti-PD-1
response. In contrast, mice deficient in both B and T cells (Rag1-/-) had unabated tumor
growth. Furthermore, we showed that human melanomas tend to have limited B cell
infiltration and that the quantity of B cells in human tumors does not correlate with
response to therapy, progression-free survival, or overall survival.
We aimed to determine whether B cell depletion is a safe approach to treatment
of irAEs caused by PD-1 inhibitors and whether this would impair their anti-tumor
activity. While the importance of tumor-infiltrating T cells in anti-tumor immunity is
indisputable, the role of B cells is less clear. Like T cells, the B cell lineage includes
subsets that may be tumor-promoting and others that could inhibit tumor growth (215).
For instance, the presence of IgA+ plasmablasts expressing PD-L1 and secreting IL-10
has been shown to render prostate cancer refractory to cytotoxic T lymphocytedependent eradication (216). In contrast, autoantibodies to a variety of melanoma
antigens have been shown to correlate with improved outcomes, higher tumor-infiltrating
CD8+ lymphocyte counts, and a greater likelihood of response to ipilimumab (217). B
cells might play a role in the tumor micro-environment beyond secretion of autoantibodies; they can modulate T cell responses either directly by presenting antigens
and activating T cells or indirectly through the formation of antigen-antibody immune
complexes that can activate myeloid and/or antigen presenting cells expressing Fc
receptors in the tumor microenvironment (218, 219). Murine squamous cell carcinoma
growth was shown to be reduced in B cell-deficient compared to wildtype mice, and
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injection of B cell-depleting antibodies in wildtype mice resulted in enhanced tumor
infiltration by CD8+ T cells (220). In addition, there is improved prognosis when B cells
are found in proximity to CD8+ T cells in the tumor microenvironments of ovarian tumors
(221). Despite these findings, however, it is unclear whether the immune-stimulating
effects of B cells are clinically meaningful in the setting of metastatic melanoma treated
with immune checkpoint inhibitors. Our data show a lack of association between
intratumoral B cell content and response to PD-1 inhibitors in human samples,
suggesting that B cells do not play a major role in anti-tumor immunity in the setting of
PD-1 inhibitor therapy. Instead, anti-tumor immunity may rely mostly on T cell
disinhibition or Treg depletion, leading to the activation of effector T cells targeting the
tumor.
Since anti-CD20 antibodies such as rituximab are currently the primary modality
for depleting B cells, we tested anti-CD20 antibodies in two murine tumor models. The
first is the MC38 colon cancer model, which is relatively sensitive to immune checkpoint
inhibitors, including both those targeting PD-1 and CTLA-4 (206). We also employed the
UV-mutagenized, neoantigen-rich YUMMER1.7 cell line as a second murine cancer
model. As shown in chapter 1C, these cells are partially sensitive to PD-1 inhibition since
anti-PD-1 treatment results in both complete and partial responses in mouse subsets
(187). We showed that B cell inhibition with anti-CD20 antibodies does not impair the
anti-tumor immune response induced by PD-1 inhibition in either model. This lends
preclinical support for the use of anti-CD20 antibodies to treat steroid-refractory irAEs in
patients with good-to-moderate clinical responses or stable disease.
Our third murine approach using the spontaneous regression model of
YUMMER1.7 in muMT mice provides further evidence that the use of therapies targeting
B cells is warranted in patients that may require them for autoimmune toxicities induced
by immune checkpoint inhibitors. muMT mice, which lack B cells due to biallelic
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inactivation of the Ighm gene, reject tumor cells as efficiently as wildtype mice. We
tested the efficacy of anti-PD-1 therapy in muMT mice using MC38 cells and found no
statistically significant difference in survival compared to wildtype C57Bl/6J mice. We
therefore conclude that B cells are not required for either endogenous or anti-PD-1elicited anti-tumor immune responses in C57Bl/6J mice.
As immune checkpoint inhibitors are gaining approval for the treatment of
multiple tumor types, the incidence of autoimmune toxicities is likely to rise, and
previously undescribed adverse events, such as fulminant myocarditis, have only
recently been reported (222). Some of these toxicities, such as autoimmune hemolytic
anemia and bullous pemphigoid, are known to be antibody-mediated and may be more
likely to respond to rituximab (171). Other toxicities, such as type I diabetes, rheumatoid
arthritis, and multiple sclerosis, are thought to be predominantly T cell-mediated,
although clinical trials of anti-B cell therapy in both rheumatoid arthritis and multiple
sclerosis have shown some efficacy, further supporting the use of anti-CD20 antibodies
for irAEs (223). Several groups have already reported successful use of rituximab for the
treatment of certain irAEs induced by both ipilimumab and nivolumab (Figure 2.1) (171,
200-203, 205).
Patients with underlying autoimmune disorders who require immune therapy for
malignancies pose an additional challenge. To date, these patients have not been
formally studied, and the safety of immune checkpoint inhibitors in this setting remains
unclear. Case series suggest that immunotherapy may be unsafe in a subset of these
patients (224). Once immune checkpoint inhibitors are initiated in patients with
underlying autoimmunity, their diseases often flare, and additional adverse events can
be seen. Given that rituximab therapy is already entertained for certain autoimmune
disorders such as multiple sclerosis (225), our results support studying the use of
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rituximab in the setting of immune checkpoint inhibitor-exacerbated autoimmunity as
well.

Conclusion
The experiments described in this chapter provide evidence that tumor-infiltrating
B cells are not required for effective immune checkpoint inhibitor-induced anti-tumor
immune response. We first used animal models of melanoma and colon carcinoma to
demonstrate that neither B cell depletion nor deficiency affect tumor growth and overall
survival in mice treated with PD-1 inhibitors. We then used human melanoma samples to
show that there is no association between the density of tumor-infiltrating B cells and
response to PD-1 inhibitors. Taken together, these studies support further research into
the use of B cell-inhibiting therapies both in patients who develop steroid-refractory irAEs
as well as in patients with underlying autoimmune disorders who require immune
checkpoint inhibitors.
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Chapter Three: Myeloid and T Cell-Targeted Immunotherapies Synergize and
Result in Durable Tumor Remission in Multiple Murine Cancer Models

Background and Hypothesis
Immune checkpoint inhibitors have revolutionized the management of metastatic
melanoma, offering increased progression-free and overall survival when compared to
both chemotherapy and targeted therapies. As discussed in chapter 1B, however, only a
subset of melanoma patients respond to immune checkpoint inhibition, and a significant
proportion of those who do respond will go on to develop acquired resistance to these
medications. One proposed mechanism for this resistance involves myeloid-derived
elements of the tumor microenvironment including tumor associated macrophages
(TAM), tumor-associated neutrophils (TAN), and myeloid-derived suppressor cells
(MDSC) (8). On the one hand, TAMs can function to enhance immune responses
through antigen presentation and direct cytotoxicity, consistent with the classical, proinflammatory M1 phenotype (226). On the other hand, however, TAMs may favor tumor
progression through a number of functions including secretion of pro-proliferative factors
such as insulin-like growth factor (IGF), pro-angiogenic factors such as VEGF and
platelet-derived growth factor (PDGF), and pro-invasive factors such as matrix
metalloproteinases (MMP) (227). They are also thought to inhibit anti-tumor immune
responses through release of immunosuppressive cytokines including IL-10 and TGFβ,
among others, consistent with the more anti-inflammatory M2 phenotype (228, 229).
Indeed, as described with YUMM tumors in chapter 1C, human melanomas with sparse
TILs yet dense TAMs are poorly responsive to immune checkpoint inhibitor therapy
(230).
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Given that these myeloid elements have the potential to both help and hinder
tumor formation, there is much interest in interventions that may push these cells toward
a more tumor-suppressive phenotype. One such intervention involves blockade of
colony-stimulating factor-1 receptor (CSF-1R), a receptor that promotes the proliferation
and maturation of monocytes and their derivatives when bound to its ligand, CSF-1
(231). Blockade or deletion of CSF-1R has been shown to reduce TAMs (232, 233) and
improve therapeutic responses in both animal tumor models and human tumors (234,
235). Another possible intervention involves treatment with agonistic antibodies to CD40,
a stimulatory receptor expressed on B cells, macrophages, and dendritic cells that
enhances antigen presentation (236, 237). CD40 agonism has been shown to reduce
resistance to immune checkpoint inhibition in human tumors (236) and to increase
expression of MHC molecules, co-stimulatory molecules, and proinflammatory cytokines
including IFNγ by TAMs (238).
We aimed to assess the impact of these myeloid-targeting therapies on the
immune checkpoint inhibitor-induced anti-tumor immune response. To explore this
question, we used the YUMMER1.7 murine melanoma and RENCA murine renal cell
carcinoma models to determine the effect of supplementing PD-1 inhibition with CD40
agonism and/or CSF-1R antagonism. We additionally assessed the effects of triple antiPD-1/CD40 agonist/CSF-1R antagonist therapy on tumors formed from YUMMER1.7
cells deficient in either the IFNγ receptor (IFNγR) or β2 microglobulin (β2M), a necessary
component of the MHC class I molecule that is upregulated downsteam of IFNγR
activation (239). We hypothesized that tumor regression and survival would be greater in
mice treated with triple therapy than in those treated with double therapy, monotherapy,
or control therapy. We further hypothesized that treatment with triple therapy would
correspond to increased secretion of pro-inflammatory cytokines. Finally, we
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hypothesized that mice bearing tumors deficient in IFNγR or β2M would fail to exhibit
increased survival over control conditions when treated with triple therapy.

Methods
Cell lines and tissue culture
The YUMMER1.7 melanoma model was described in chapter 1C. IFNγRdeficient and β2M-deficient YUMMER1.7 lines were generated using CRISPR/Cas9mediated gene deletion. The RENCA line was derived from a renal cortical
adenocarcinoma that arose spontaneously in a BALB/c mouse (240). The YUMMER1.7
lines were maintained in DMEM/F12 media containing 10% FBS, 1% nonessential
amino acids, and 1% penicillin-streptomycin. The RENCA lines were maintained in
RPMI-1640 media with 10% FBS, 1% nonessential amino acids, 1% penicillinstreptomycin, 1% sodium pyruvate, and 1% L-glutamine.

Murine models
Wildtype YUMMER1.7, IFNγR-deficient YUMMER1.7, and β2M-deficient
YUMMER1.7 tumor cells were implanted subcutaneously into the right hind flanks of
wildtype C57Bl/6J mice from Jackson Laboratory. RENCA tumor cells were implanted
subcutaneously into the right hind flanks of wildtype BALB/c mice from Jackson
Laboratory. To form tumors from wildtype YUMMER1.7 or IFNγR-deficient YUMMER1.7
cells, 500,000 cells were implanted as described in chapter 1C. To form tumors from
β2M-deficient YUMMER1.7 cells, 1,000,000 cells were implanted. To form RENCA
tumors, 500,000 cells were implanted. Mice were euthanized according to humane
endpoints when tumors reached 1.5 cm in maximum dimension or when tumors
ulcerated.
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Drug treatment
Treatments were initiated on post-injection day 7 when tumors were roughly 50100 mm3 in size and were administered twice weekly for a total of 6 doses. Treatment
with anti-PD-1 antibody (RMP1-14, Bio X Cell) was administered at a dose of 8 mg/kg in
sterile saline by intraperitoneal injection. Treatment with anti-CD40 agonist antibody
(FGK4.5, Bio X Cell) was administered at a dose of 8 mg/kg in sterile saline by
intraperitoneal injection. Treatment with anti-CSF-1R antibody (mCSF1R.2-mG1, BristolMyers Squibb) was administered at a dose of 8 mg/kg in sterile saline by intraperitoneal
injection. Saline vehicle was administered to control animals.

Cytokine analysis
Blood was obtained via retro-orbital collection into heparinized rubes on day 2 of
treatment. Plasma was prepared and stored at -80C. Cytokine levels in plasma were
determined using the Mouse Cytokine Array 31-Plex by Eve Technologies.

Statistical analyses
Prism version 7.0 software was used. Difference in survival was assessed using
the Kaplan-Meier method, and statistical significance was determined using the log-rank
(Mantel-Cox) test.

Results
80 mice with established YUMMER1.7 tumors were divided into eight treatment
groups with 10 mice per group: control, anti-PD-1, anti-CD40, anti-CSF-1R, anti-PD-1 +
anti-CD40, anti-PD-1 + anti-CSF-1R, anti-CD40 + anti-CSF-1R, and anti-PD-1 + antiCD40 + anti-CSF-1R. As shown in the Kaplan-Meier curves in Figure 3.1A, survival did
not significantly differ among control mice and those treated with anti-PD-1 or anti-CSF-
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1R monotherapy. Survival was significantly increased, however, in mice treated with
anti-CD40 relative to control mice. Supplementing anti-CD40 with anti-CSF-1R resulted
in increased survival, although this effect did not reach statistical significance in this
study. Survival was also significantly increased in mice treated with either anti-CD40 +
anti-CSF-1R or anti-PD-1 + anti-CD40 + anti-CSF-1R relative to both control mice and
those receiving anti-PD-1 alone. Survival did not increase significantly when anti-PD-1
was added to anti-CD40 + anti-CSF-1R. Tumor volumes for the control, anti-PD-1, antiCD40 + anti-CSF-1R, and anti-PD-1 + anti-CD40 + anti-CSF-1R groups are shown by
spider plots in Figure 3.2A.
Another 40 mice with established RENCA tumors were divided into four
treatment groups with 10 mice per group: control, anti-PD-1, anti-CD40 + anti-CSF-1R,
and anti-PD-1 + anti-CD40 + anti-CSF-1R. As with the YUMMER1.7 experiment, we
showed that survival did not significantly differ among control mice and those treated
with anti-PD-1 monotherapy. Survival was significantly increased, however, in mice
treated with either anti-CD40 + anti-CSF-1R or anti-PD-1 + anti-CD40 + anti-CSF-1R
relative to both control mice and those receiving anti-PD-1 alone. Survival did not
increase significantly when anti-PD-1 was added to anti-CD40 + anti-CSF-1R. The
survival and growth curves are shown in Figures 3.1B and 3.2B, respectively.
To explore whether IFNγ signaling is required for the effect of triple therapy on
tumor growth, we performed a pilot experiment in which 6 mice with established IFNγRdeficient YUMMER1.7 tumors and 6 mice with established β2M-deficient YUMMER1.7
tumors were divided into two treatment groups containing 3 mice per group: control and
anti-PD-1 + anti-CD40 + anti-CSF-1R. Prior experiments have demonstrated that
treatment with anti-PD-1 monotherapy does not significantly increase survival in mice
bearing tumors formed from these YUMMER1.7 lines (data not shown). As shown in the
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Figure 3.1: Supplementing anti-PD-1 therapy with CD40 agonist and CSF-1R
antagonist increases survival in murine models of melanoma (YUMMER1.7) and
renal cell carcinoma (RENCA). A. Survival of YUMMER1.7 tumor-bearing mice treated
with saline (ctrl), anti-PD-1, anti-CD40, anti-CSF-1R, anti-PD-1 + anti-CD40, anti-PD-1 +
anti-CSF-1R, anti-CD40 + anti-CSF-1R, or anti-PD-1 + anti-CD40 + anti-CSF-1R. Ctrl vs.
anti-PD-1 p=0.11; Ctrl vs. anti-CD40 p=0.0001; Ctrl vs. anti-CSF-1R p=0.33; Ctrl vs. antiCD40 + anti-CSF-1R p<0.0001; Ctrl vs. anti-PD-1 + anti-CD40 + anti-CSF-1R p<0.0001;
anti-PD-1 vs. anti-CD40 + anti-CSF-1R p=0.0022; anti-PD-1 vs. anti-PD-1 + anti-CD40 +
anti-CSF-1R p<0.0001; anti-CD40 vs. anti-CD40 + anti-CSF-1R p = 0.079; anti-CD40 +
anti-CSF-1R vs. anti-PD-1 + anti-CD40 + anti-CSF-1R p=0.23. B. Survival of RENCA
tumor-bearing mice treated with saline (ctrl), anti-PD-1, anti-CD40 + anti-CSF-1R, or
anti-PD-1 + anti-CD40 + anti-CSF-1R. Ctrl vs. anti-PD-1 p=0.55; Ctrl vs. anti-CD40 +
anti-CSF-1R p=0.0054; Ctrl vs. anti-PD-1 + anti-CD40 + anti-CSF-1R p=0.0004; anti-PD1 vs. anti-CD40 + anti-CSF-1R p=0.013; anti-PD-1 vs. anti-PD-1 + anti-CD40 + antiCSF-1R p=0.0001; anti-CD40 + anti-CSF-1R vs. anti-PD-1 + anti-CD40 + anti-CSF-1R
p=0.30.
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A

YUMMER1.7

B

RENCA

Figure 3.2: Supplementing anti-PD-1 therapy with CD40 agonist and CSF-1R
antagonist increases survival in murine models of melanoma (YUMMER1.7) and
renal cell carcinoma (RENCA). A. Spider plots showing YUMMER1.7 tumor growth in
individual mice from Figure 3.1A. B. Spider plots showing RENCA tumor growth in
individual mice from Figure 3.1B.
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Kaplan-Meier curves in Figure 3.3, however, survival is significantly increased in mice
receiving anti-PD-1 + anti-CD40 + anti-CSF-1R relative to those receiving control
treatment for mice bearing both IFNγR-deficient (A) and β2M-deficient tumors (B).
Tumor volumes are shown by spider plots in Figure 3.4A and B.

Figure 3.3: Triple therapy increases survival in mice bearing IFNγ-nonresponsive
tumors. A. Survival of mice bearing IFNγR-deficient YUMMER1.7 tumors treated with
saline (ctrl) or anti-PD-1 + anti-CD40 + anti-CSF-1R. p=0.022 B. Survival of mice bearing
β2M-deficient YUMMER1.7 tumors treated with saline (ctrl) or anti-PD-1 + anti-CD40 +
anti-CSF-1R. p=0.025.

63

A

IFNGR -/Tumor volume (mm3)

1500

1000

ctrl
α-PD1 + α-CD40 + α-CSF1R

500

0

0

10

20

30

40

Days

B

B2M -/Tumor volume (mm3)

1500

1000

ctrl
α-PD1 + α-CD40 + α-CSF1R

500

0

0

10

20

30

40

Days

Figure 3.4: Triple therapy slows tumor growth in mice bearing IFNγ-nonresponsive
tumors. A. Spider plots showing IFNγR-deficient YUMMER1.7 tumor growth in
individual mice from Figure 3.3A. B. Spider plots showing β2M-deficient YUMMER1.7
tumor growth in individual mice from Figure 3.3B.

Figure 3.5 shows cytokine levels in mice receiving the various treatments. Blood
from mice that received CD40 agonist either as monotherapy or in combination with
other treatments contained significantly higher levels of G-CSF, IFNγ, TNFα, IL-6, IL-16,
CCL2, CCL5, CXCL1, CXCL9, CCL17, CCL19, CCL20, CCL22, and TIMP1 when
compared to blood from mice that did not receive CD40 agonist. Additionally, levels of
IL-10 and IL-12 were significantly elevated in blood from mice treated with CD40 agonist
monotherapy, CD40 agonist/CSF-1R antagonist dual therapy, and triple therapy (but not
anti-PD-1/CD40 agonist dual therapy) when compared to those treated with control,
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CSF-1R monotherapy, or anti-PD-1 monotherapy. Levels of CXCL10 were significantly
increased in mice receiving triple therapy relative to those receiving all other therapies.
The levels of GM-CSF, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-7, IL-9, IL-13, IL-15, IL-17,
CXCL5, VEGF, and IFNB1 did not differ significantly among treatment groups.
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Figure 3.5: Cytokine concentrations in peripheral blood. Error bars represent 95%
confidence intervals.
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Discussion
We employed murine models of two tumors commonly treated with immune
checkpoint inhibitors - melanoma and renal cell carcinoma – to assess the potential for
myeloid-targeting therapies to supplement the anti-tumor immune responses induced by
PD-1 inhibition. In both models, triple therapy with PD-1 inhibition, CD40 agonism, and
CSF-1R antagonism resulted in increased survival relative to both control therapy and
monotherapy with PD-1 inhibition. In fact, as shown by the growth curves in Figure 3.2,
the majority of tumors treated with triple therapy regressed completely, in stark contrast
to those treated with anti-PD-1 monotherapy.
We did not, however, observe a significant survival advantage in mice treated
with triple therapy relative to those treated with anti-CD40 + anti-CSF-1R, suggesting
that the contribution of PD-1 inhibition to the increases in survival seen with triple
therapy is minimal. This may be explained by the fact that both tumor lines employed in
this study are relatively insensitive to anti-PD-1 monotherapy (Figures 3.1 and 3.2), a
property shared by a significant proportion of melanomas and other typically
immunogenic cancers. Our observation that triple therapy increases survival over PD-1
monotherapy in these models therefore lends support to the idea that myeloid-targeted
therapies may show promise in treating patients with immune checkpoint inhibitorresistant tumors. It should also be noted that the difference in survival, particularly in the
YUMMER1.7 model, may have reached significance with larger sample sizes or a longer
window of observation, as complete tumor regression was more commonly observed in
mice treated with the triple therapy than with anti-CD40 + anti-CSF-1R therapy (Figure
3.2).
We additionally observed that triple therapy enhances survival even in mice
bearing tumors that are unable to transduce IFNγ signaling, challenging the notion that
IFNγ is necessary for T cell-mediated tumor killing. It is possible that T cells may be
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engaged through an IFNγ-independent mechanism that becomes upregulated in the
presence of CD40 agonist and CSF-1R antagonist. This is unlikely, however, as Perry,
et al. showed that antibody-mediated IFNγ blockade eliminates the anti-tumor effects of
double therapy (241). Importantly, none of the YUMMER1.7 tumors deficient in IFNγR or
β2M completely regressed, and only one mouse bearing an IFNγR-deficient tumor
survived to the end of the observation window, at which point its tumor was growing
rather than regressing. The increased survival observed when treating IFNγR or β2Mdeficient tumors with triple therapy was thus due to slowed tumor growth instead of
tumor regression. One explanation for this effect is that myeloid cell stimulation may
promote a burst of local inflammation that perturbs initial tumor growth. In order to better
define this growth phenotype, we plan to repeat these experiments using larger cohorts
and an extended observation period.
Given the potential utility of these myeloid therapies in treating immune
checkpoint inhibitor-resistant tumors, it will be important to define the cellular
mechanisms responsible for the observed survival benefits. Perry, et al. used combined
CD40 agonist and CSF-1R antagonist to treat melanomas derived from the poorly
immunogenic BRAFV600E/PTEN-/- GEMM discussed in chapter 1C (241). This
combination therapy was found to suppress tumor growth despite increasing the density
of TAMs. Analysis of RNA transcription revealed that monotherapy with CD40 agonist
increased TAM expression of Tnfa, Ifng, Il12b, and Cxcl9, all genes encoding proinflammatory cytokines, while monotherapy with CSF-1R antagonist reduced expression
of Cd36 and Fabp4, genes involved in lipid homeostasis. Single-cell secretion profiling
revealed that TAMs from dual-treated tumors exhibited increased secretion of M1-type
cytokines including TNFα, IL-6, IL-12, CCL3, CXCL1, and IFNγ and reduced secretion of
the M2-type factor, MMP9. Additionally, this shift in TAM phenotype was shown to
induce increased secretion of IFNγ by tumor-infiltrating T cells. Importantly, the anti-
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tumor effects of dual therapy were abrogated by T cell depletion and antibody-mediated
blockade of TNFα or IFNγ (241).
Wiehagen, et al. similarly employed dual CD40 agonist/CSF-1R antagonist
therapy to treat murine tumors formed from injected MC38 or CT26 colon carcinoma
cells (242). As observed by Perry et al., dual therapy was shown to suppress tumor
growth in a T cell-dependent fashion, and TAMs were shown to shift their expression
profiles toward a more pro-inflammatory phenotype. This included upregulation of costimulatory molecules and inflammatory cytokines including TNFα, IL-6, IL-12, IL-23,
GM-CSF and IFNγ. In addition, both tumor antigen-specific T cells and CD103+ dendritic
cells that are known to cross-present tumor antigens to T cells were shown to
accumulate more in the draining lymph nodes of dual therapy-treated mice than in
monotherapy-treated or control mice. Finally, dual treatment was found to increase both
the density of CD8+ TILs and the effector function of these TILs. Taken together, the
results of these two studies elicit a model of tumor suppression in which CD40 agonism
and CSF-1R inhibition shift TAM expression profiles toward a more pro-inflammatory
phenotype, thereby facilitating tumor killing by T cells.
Our findings are in concert with those of Perry, et al. and Wiehagan, et al.,
demonstrating that double therapy with CD40 agonist/CSF-1R antagonist results in
increased secretion of proinflammatory cytokines and an improved anti-tumor immune
response. We further demonstrate that combining myeloid-targeted therapy with PD-1
blockade increases survival relative to PD-1 monotherapy. Treatment with CD40 agonist
was found to upregulate cytokines associated with acute inflammation including G-CSF,
IL-6, and TNFα, as well as cytokines associated with chemotaxis of activated T cells,
including IL-16, CCL5, CXCL9, CCL17, CCL19, CCL20, and CCL22. Increased levels of
IL-12 and IFNγ were also observed with CD40 agonist therapy, suggesting that its antitumor effects may be partially mediated by the promotion of TH1 differentiation, as has
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been previously described in the literature (243). Interestingly, levels of IL-10, a
classically anti-inflammatory cytokine, were also observed to increase in mice treated
with CD40 agonist. This effect was abrogated, however, by co-treatment with an IL-6
receptor antagonist (data not shown), suggesting that IL-6 may play a role in engaging
anti-inflammatory components of the tumor microenvironment including regulatory T
cells (244).
Our analysis also revealed that CD40 agonist therapy upregulates the MMP
inhibitor, TIMP1. In addition to its canonical role as a regulator of extracellular matrix
catabolism, TIMP1 has also been shown to promote cell growth and division through
several mechanisms including mitogen activation and inhibition of MMP-mediated
growth factor receptor shedding from cell surfaces (245). TIMP1 is often overexpressed
in tumor tissue relative to normal tissue (246-248), and it may impair immune clearance
of tumor cells by enhancing IL-10 expression (249). Given this potential for TIMP-1 to
promote tumor growth, it will be important to further elucidate its role in the growth
phenotype observed with CD40 agonist therapy.
Treatment with anti-PD-1 monotherapy was not associated with significant
increases in IL-2, IFNγ, or TNFα, a finding that mirrors the lack of a significant survival
benefit in mice treated with anti-PD-1 monotherapy relative to control mice. This lends
further support to the use of the YUMMER1.7 and RENCA cell lines to model tumors
resistant to immune checkpoint inhibitor therapy. The addition of anti-PD-1 to CD40
agonist/CSF-1R antagonist dual therapy, however, resulted in significant upregulation of
CXCL10, a cytokine that promotes monocyte, NK cell, and T cell chemotaxis while
inhibiting angiogenesis (250). Signaling via CXCL10 may therefore explain the trend
toward increased survival in mice receiving triple therapy relative to those receiving dual
therapy. In order to better define the changes in gene expression occurring in myeloid
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and T cells when double therapy is added to PD-1 blockade, we are pursuing single cell
RNA sequencing using tumor samples from the various treatment groups.

Conclusion
In summary, the experiments detailed in this chapter demonstrate that
supplementing PD-1 inhibition with CD40 agonist and CSF-1R antagonist significantly
increases survival relative to anti-PD-1 monotherapy in mice bearing immune checkpoint
inhibitor-resistant melanoma and renal cell carcinoma tumors. Dual therapy with CD40
agonist and CSF-1R antagonist leads to upregulation of cytokines that promote acute
inflammation, T cell chemotaxis, and TH1 differentiation, while triple therapy with CD40
agonist, CSF-1R antagonist, and PD-1 inhibition uniquely upregulates CXCL10, a
cytokine that promotes both lymphoid and myeloid chemotaxis and attenuates
angiogenesis. Taken together, these studies support further research into the safety and
efficacy of adding CD40 agonist and CSF-1R antagonist to the treatment regimens of
patients with immune checkpoint inhibitor-resistant tumors.
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Chapter Four: Tumor Resection and Rechallenge as a Model for Failed and
Successful Anti-tumor Immune Responses

Background and Hypothesis
Melanomas are highly immunogenic neoplasms, as evidenced by their
propensity to become infiltrated by T cells and, in some cases, to spontaneously
regress. Despite this, only 50-60% of patients with metastatic melanoma respond to
combined anti-PD-1/anti-CTLA-4 therapy (8). Chapter three discussed the role of
immunosuppressive elements of the tumor microenvironment in the immune system’s
inability to control tumor progression in this subset of nonresponders. Another proposed
explanation for this failure, however, involves acquired T cell dysfunction in the setting of
prolonged antigen exposure, as has been described in the setting of chronic viral
infections (251). Indeed, TILs often produce low levels of effector cytokines and express
many of the same inhibitory receptors found on virally exhausted T cells (252-254).
To elucidate the role of T cell dysfunction in the progression of melanoma
specifically, it will be crucial to contrast T cell functionality in successful and failed antimelanoma immune responses within individual organisms. To address this need, we
developed a model involving resection of YUMMER1.7 tumors and subsequent
rechallenge with YUMMER1.7 cells. Pilot studies suggest that the cells injected during
these rechallenges are rejected through a memory response. Based on these studies
and on data presented in the previous chapter, we believe that immunosuppressive
elements in the tumor microenvironment play a larger role in melanoma’s resistance to
immunotherapy than does T cell dysfunction. Thus, we hypothesized that injecting mice
with large numbers of YUMMER1.7 cells subsequent to resection of preformed
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YUMMER1.7 tumors would elicit an effective memory response and fail to produce new
tumors.

Methods
Cell lines and tissue culture
YUMMER1.7 cells expressing green fluorescent protein (GFP) fused to histone
2B (H2B) were generated using a lentivirus vector via standard methods (255). Multiple
resulting sublines were evaluated, and one line that exhibited growth properties and
immunogenicity similar to wildtype YUMMER1.7 cells was selected and expanded. Cell
lines were maintained in DMEM/F12 media containing 10% FBS, 1% nonessential
amino acids, and 1% penicillin-streptomycin.

Murine models
YUMMER1.7-H2B-GFP tumor cells were implanted subcutaneously into the right
hind flanks of wildtype C57Bl/6J mice from Jackson Laboratory. To form tumors,
500,000 cells were implanted. For spontaneous rejection, 50,000 cells were implanted.
To generate mice that could launch memory responses, 100,000 cells were implanted
and rejected as described in chapter 1C. Mice were euthanized according to humane
endpoints if tumors reached 1.5 cm in maximum dimension or became ulcerated.

Surgeries
Surgeries were performed on day 12 post-injection. Tumor-bearing mice were
anesthetized using a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine
administered by intraperitoneal injection. Vaseline was applied to the eyes to prevent
corneal damage. Skin surrounding the tumors was shaved and cleaned three times with
ethanol. Autoclaved forceps and surgical scissors were used to resect tumors and
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undermine the surrounding skin. Incisions were sutured using 4-0 fast absorbing plain
gut, and surgical glue was applied over sutures to provide extra support. Post-operative
analgesia was provided with 2 mg/kg meloxicam solution administered by intraperitoneal
injection. Adequate anesthesia was assessed throughout the procedure using toe
pinching. Post-operative mice were housed in single-occupancy cages with Space Gels
placed underneath to provide thermal support. Mice were continually monitored until
they recovered from anesthesia and once daily afterwards. Wound dehiscence prompted
immediate repair or euthanasia. Mock surgeries were performed on post-injection day 1
using the protocols described above. 3 cm incisions were made in a rostral-to-caudal
direction over the left (non-tumor bearing) hind flank.

Memory timecourse
Mice that had previously rejected 100,000-cell injections were rechallenged with
500,000 YUMMER1.7-H2B-GFP cells. Tissue samples containing GFP-positive tumor
cells were harvested under a fluorescent microscope at 1 hour, 6 hours, 1 day, 2 days, 3
days, 4 days, 7 days, and 9 days following injection. Samples were formalin-fixed and
paraffin-embedded using standard methods. Immunohistochemistry was performed with
standard methods using a GFP antibody to identify tumor cells, an anti-mouse CD3
antibody to identify T lymphocytes, and an anti-mouse cleaved caspase 3 antibody to
identify apoptotic cells. Histology and immunohistochemistry were reviewed by William
Damsky, MD, PhD and Marcus Bosenberg, MD, PhD.

Results
The tissue damage inherent to surgery is likely to generate damage-associated
molecular patterns that stimulate innate immune cells. This raises the question of
whether incision-specific immune engagement would impact the anti-tumor immune
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response. To address this, 10 wildtype C57Bl/6J mice underwent mock surgeries to their
left flanks while 10 age-matched control mice did not. On post-operative day 14, mice in
each group received injections of either 500,000 (5 mice per group) or 50,000 (5 mice
per group) YUMMER1.7-H2B-GFP cells on their right flanks. As shown in the KaplanMeier curves in Figure 4.1A, survival did not differ when mock surgeries were performed
in mice that received 500,000-cell injections, and all mice reached endpoint by postinjection day 25. Similarly, survival did not differ when mock surgeries were performed in
mice that received 50,000-cell injections (Figure 4.1B), with 40% of mice rejecting tumor
cells in both groups.
Next, we set out to determine whether post-operative rechallenges would result
in successful memory responses. 30 wildtype C57Bl/6J mice received injections of
500,000 YUMMER1.7-H2B-GFP cells into their right flanks, and another 16 wildtype
mice were designated as controls. The 30 experimental mice developed palpable tumors
by post-injection day 7, and these tumors were resected on post-injection day 12 when
they were approximately 1 cm in maximal dimension. This timepoint was chosen to allow
for adequate immune exposure to tumor cells (Figure 1C.10) (187) while avoiding tumor
invasion into the underlying back fascia and musculature, which would greatly increase
the likelihood of incomplete resection and postoperative complications. Lack of invasion
was grossly confirmed upon observation of resected tumors confined within their tumor
capsules (Figure 4.2C). Of the 30 surgical mice, 2 were euthanized due to intraoperative
complications (1 pneumothorax and 1 hernia) and 1 was euthanized on post-operative
day 3 due to wound dehiscence. Example pre- and post-operative images are shown in
Figure 4.2A-C.
Post-operative mice were rechallenged on post-injection day 30 (post-operative
day 18) to minimize the impact of immune activation related to wound repair. Of the 27
surviving mice, 20 were rechallenged with 500,000 YUMMER1.7-H2B-GFP cells and 7
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were rechallenged with 50,000 YUMMER1.7-H2B-GFP cells. Rechallenge injections
were administered into the left flanks to facilitate distinction between resected tumor
regrowth and new tumor growth. Also at this time point, the 16 control mice received
injections of either 500,000 (8 mice) or 50,000 (8 mice) YUMMER1.7-H2B-GFP cells into
their left flanks. The cells administered to both post-operative and control mice were
taken from the same culture plate. None of the 27 post-operative mice grew tumors
following rechallenge while all of the control mice injected with 500,000 cells and 50% of
the control mice injected with 50,000 cells grew tumors and reached endpoint by postinjection day 30, as shown by the Kaplan-Meier curves in Figure 4.3. Rechallenged mice
were observed for 6 months and exhibited no tumor growth during that period.
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Figure 4.1: Mock surgery does not affect tumor growth. A. Survival of mice injected
with 500,000 YUMMER1.7-H2B-GFP cells with and without mock surgery. p=0.9241. B.
Survival of mice injected with 50,000 YUMMER1.7-H2B-GFP cells with and without
mock surgery. p=0.8268. 40% of mice rejected tumor cells regardless of mock surgery.
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Figure 4.2: Tumor resection surgery. A. Pre-operative YUMMER1.7-H2B-GFP
melanoma tumor visible on right posterior flank. B. Surgical wound repaired with suture
and surgical glue following tumor resection. C. Resected tumor contained within capsule.
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Figure 4.3: Post-surgical rechallenges provoke an immune memory response. A.
Survival of mice injected with 50,000 YUMMER1.7-H2B-GFP cells with and without prior
tumor resection. p=0.0365. B. Survival of mice injected with 500,000 YUMMER1.7-H2BGFP cells with and without prior tumor resection. p<0.0001.
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To determine the kinetics of the anti-tumor immune memory response, we used
16 “memory mice” that had previously rejected injections of 100,000 YUMMER1.7-H2BGFP cells. Injections of 500,000 YUMMER1.7-H2B-GFP cells were administered to their
left flanks, contralateral to the sites of their previous injections. Mice were euthanized,
and tissue containing tumor cells was resected under fluorescent microscopy at the
following post-injection time points: 1 hour (1 mouse), 6 hours (1 mouse), 1 day (2 mice),
2 days (2 mice), 3 days (2 mice), 4 days (2 mice), 7 days (1 mouse), and 9 days (1
mouse). These timepoints were selected based on pilot data suggesting that tumor
killing was occurring between 24 hours and 5 days post-injection. The remaining 4 mice
were used as controls to verify that the tumor cells were provoking a memory response;
none developed tumors. Immunohistochemical staining for CD3 demonstrated that T-cell
infiltration and tumor killing peaked at 2 days post-injection and gradually diminished
through 9 days post-injection. Representative histologic images are shown in Figure 4.4.

A

B

C

Figure 4.4: The immune memory response peaks on post-injection day 2. CD3
staining (brown) demonstrates that T cell infiltration and tumor killing is minimal at 24
hours post-rechallenge (A), peaks at 48 hours post-rechallenge (B), and diminishes by 9
days post-rechallenge.
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Discussion
A successful adaptive immune response begins with an expansion phase during
which T cells recognize MHC-bound antigen, proliferate, and clear the antigen. This
phase is followed by a contraction phase during which most antigen-specific T cells
undergo apoptosis, and the remaining T cells differentiate into memory cells (256). In
contrast to such successful immune responses, however, several aberrant states of T
cell activation and differentiation, which result in varying degrees of T cell dysfunction,
have been described in the literature (256). Perhaps the best studied of these aberrant
states occurs with chronic exposure to viral infections including murine lymphocytic
choriomeningitis virus (LCMV) clone 3. In this setting, CD8+ T lymphocytes initially
proliferate and acquire effector function as seen in successful immune responses. Over
time, however, they sequentially lose the ability to produce IL-2, TNFα, and IFNγ (251)
and concurrently upregulate expression of inhibitory receptors including PD-1, LAG-3,
CD160, 2B4, TIM-3, BTLA, and CTLA-4 (257). In this “exhausted state,” T cells are able
to maintain a semblance of control over the infection without eradicating it, a property
thought to mitigate the potential for autoimmune toxicity that would accompany a strong
antiviral response (258).
To study the role of T cell exhaustion in cancer progression, Schietinger, et al.
used a tamoxifen-inducible, autochthonous hepatocellular carcinoma model to show that
genes associated with T cell effector function are downregulated with prolonged
exposure to tumor antigen (259). They further showed that the capacity for functional
restoration by antigen removal or inhibitory receptor blockade diminishes with time.
Selective upregulation of genes encoding epigenetic modifiers occurred in concert with
this loss of restorative capacity, suggesting that this dysfunctional genetic program
becomes imprinted in tumor-specific T cells. Notably, several differences in gene
expression profiles were observed between the exhausted T cells described in the
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context of chronic viral infections and dysfunctional tumor-specific T cells. This suggests
that although certain changes in gene expression occur with chronic exposure to
antigens regardless of their nature, the specific flavor of T cell dysfunction that occurs is
context-dependent.
To explore the impact and define the characteristics of T cell dysfunction in
melanoma progression specifically, we aimed to develop a model with which to compare
T cell functionality in failed and successful anti-YUMMER1.7 immune responses. The
potential for variability in anti-tumor immunity among mice, however, threatens the
validity of conclusions drawn from experiments in which a formed tumor from one mouse
is compared to a rejecting tumor in another. We sought to address this by comparing
established YUMMER1.7 tumors to actively rejecting YUMMER1.7 tumors in the same
mice by resecting established cutaneous tumors and subsequently rechallenging postoperative mice with additional YUMMER1.7 cells to provoke an immune memory
response. We observed no tumor growth in mice rechallenged with 50,000 or 500,000
YUMMER1.7 cells, suggesting that rechallenges are indeed rejected by a robust
immune memory response. We additionally showed that the resection process itself
does not grossly impact the observed growth pattern of injected YUMMER1.7 cells.
While the existence of a robust post-operative memory response lends support to
our hypothesis that the tumor microenvironment plays a more significant role in tumor
escape than does T cell dysfunction, there remains the possibility that the T cell
populations responsible for the initial failed immune responses and the subsequent
successful responses were distinct. In order to address this possibility, we plan to pursue
a series of adoptive transfer experiments. Briefly, YUMMER1.7 cells expressing
ovalbumin (OVA) will be injected into OT-I mice whose T cells are genetically modified to
recognize an MHC-bound ovalbumin fragment (260). Tumors will be allowed to grow and
become infiltrated with T cells, after which they will be excised. TILs will be dissociated
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from tumors and will then be adoptively transferred into wildtype mice bearing
YUMMER1.7-OVA tumors. Post-transfer tumor behavior will shed light on the extent of T
cell dysfunction that occurs during an initial tumor cell challenge. In addition to adoptive
transfer experiments, we plan to perform single cell RNA sequencing on samples from
growing and rejecting tumors, paying particular attention to differences in expression of
exhaustion and activation markers among the samples.

Conclusion
In summary, we demonstrated that rechallenging mice with YUMMER1.7 tumor
cells following complete tumor excision reliably results in a robust immune memory
response and tumor rejection. We thus developed a novel protocol by which both failed
and successful anti-tumor immune responses can be studied in individual mice. This
protocol can be used in future experiments to characterize the immune infiltration
patterns, histologic features, and gene expression profiles that distinguish regressing
from escaping tumors.
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